附件99.3
讨论和
非盈利者的和解
GAAP财务指标
2024年9月30日
(未经审计)
| 定义 | ||
调整后固定费用覆盖率 按照固定费用覆盖调整后的EBITDAre除以固定费用计算得出。调整后的固定费用覆盖是流动性的补充指标，反映我们支付利息及分红给优先股东（如适用）的能力。我们的各项债务协议包含要求我们维持类似调整后的固定费用覆盖比率的契约，信用评级机构在评估和确定我们某些债券的信用评级时也会使用类似的比率。调整后的固定费用覆盖受到调整后的EBITDAre和固定费用的相同限制和条件的约束。
调整后的基金来自运营（“AFFO”） AFFO被定义为FFO在调整后排除以下影响：(i)基于股票的补偿摊销费用，(ii) 专项融资费用和债务折扣（溢价）的摊销，(iii) 直线租金，(iv) 推迟所得税，(v) 净额上下市场租赁无形资产的摊销，以及(vi)其他AFFO调整，包括：(a) 租赁激励摊销（减少直线租金），(b) 针对已发生但未报告的保险赔偿的精算准备金，和(c) 推迟收入的摊销，不包括摊入租金收入的金额，这些金额与租客资助的由我们拥有/确认的改进和租客预付款相对应。此外，AFFO在扣除定期资本支出后计算，包括第二代租赁费用和第二代租户及资本改进（“AFFO资本支出”）。所有调整反映了我们对合资企业（报告在“其他AFFO调整”中）的比例份额的实质份额和非实质份额。我们通过将适用期间的实际所有权百分比应用于按实体方式归类的相应调整项目，反映了我们对非合并合资企业的AFFO份额。对于我们不拥有100%股权的合并合资企业，我们通过根据适用期间的实际所有权百分比调整我们的AFFO，以排除适用期间的第三方所有权份额的调整项目。有关我们使用按比例份额信息及其局限性的进一步披露，请参见下文的“Nareit FFO”。我们认为AFFO是一种改善投资者对我们运营结果的理解、使期望结果、以往期间结果和与REITs间结果比较更有意义的替代性经常性盈利度量。AFFO不代表根据GAAP确定的经营活动产生的现金，不表示可用于资金需求的现金，因为它排除了通常流经我们从经营活动产生的现金流的以下项目：(i) 为期间应计的收入或费用项目的变动进行调整，(ii) 与交易相关的成本，(iii) 诉讼和解决费用，以及(iv) 重组和与解聘相关的费用。此外，AFFO还针对通常在确定经营活动现金流或流动性时不予考虑的定期资本支出进行调整。其他REITs或房地产公司可能使用不同的计算AFFO的方法，因此，我们的AFFO可能与其他REIT报告的不可比。管理层认为AFFO是我们绩效的一个有意义的补充衡量标准，经常被分析师，投资者和其他利益相关方在评估我们作为REIT的表现时使用，通过提供AFFO，我们正在协助这些利益相关方进行评估。AFFO是一项非GAAP的补充财务指标，不应被视为根据GAAP确定的净收入（损失）的替代，只有与我们按照GAAP准备的财务信息一起并作为补充考虑时才应被视为。
调整后的净营业收入和现金（调整后）净营业收入（"NOI"） 调整后的净营业收入是一项非美国通用会计准则（"GAAP"）的附加财务指标，用于评估房地产的经营绩效。调整后的净营业收入定义为房地产收入（包括租金和相关收入、居民费用和服务费用以及政府补助收入，不包括利息收入），减去物业级别的营业费用；调整后的净营业收入不包括净利润（亏损）中包括的所有其他财务报表金额。 调整后的净营业收入消除了直线租金、摊销市场租赁无形资产、终止费用、已发生但未报告的保险赔款的精算准备，以及延期社区费用收入和费用的影响。调整后的净营业收入是从合并物业的调整后净营业收入计算得出，再加上我们在非合并联营企业中的调整后净营业收入份额（根据所需期间应用我们实际持股比例计算），减去非控股权益在合并联营企业的调整后净营业收入份额（根据我们实际持股比例计算）。我们在评估自身绩效时利用我们的调整后净营业收入份额，因为我们有多个联营企业 contributing to our performance。我们无法控制非合并联营企业，我们从非合并联营企业获得的金额不代表我们针对这些项目的法律索赔。我们的调整后净营业收入份额不应被视为美国通用会计准则所要求的财务信息的替代，只能与我们根据GAAP呈报的财务信息一起或作为补充考虑。
调整后的净营业收入通常被称为“现金净营业收入”。管理层认为调整后的净营业收入是一项重要的补充指标，因为它通过仅反映在物业级别发生的收入和运营费用项目，并以不负债的基础呈现它们，提供相关且有用的信息。我们使用调整后的净营业收入来做出关于资源配置的决策，评估和比较物业级别的表现，并评估我们的合并后相同店铺（“合并后SS”）的表现，如下所述。我们相信净利润（损失）是与调整后的净营业收入最直接可比的美国通用会计准则衡量标准。由于它不反映各种被排除项，调整后的净营业收入不应被视为净利润（损失）的替代经营绩效指标。此外，我们对调整后的净营业收入的定义可能不可与其他信托或房地产公司使用的定义相比较，因为它们可能使用不同的计算方法来计算调整后的净营业收入。
营业费用通常与租赁的门诊医疗和实验室建筑以及CCRC设施有关。我们通常通过租户收回来弥补全部或部分门诊医疗和实验室物业费用，这些费用在租金和相关收入中得到确认。
合并债务报告于我们的综合基本报表中的银行信用额度、商业票据、定期贷款、高级无担保票据及抵押贷款的账面价值。
合并总资产在加回积压折旧及摊销后，我们合并基本报表中报告的资产总额，不包括对我们非合并合资企业的投资和预付款项。合并总资产是我们财务状况的一个补充指标，与债务相关的指标一起使用，使管理层和投资者能够分析我们的杠杆情况，并将我们的杠杆情况与其他公司进行比较。
综合抵押债务 按揭及其他由房地产业担保的债务，根据我们的综合基本报表所报告。
继续护理养老社区（CCRC） 一个为老年人提供至少三个护理层次的住所（即独立生活、辅助生活和熟练护理）的设施。
债务投资 贷款以房地产直接担保和梅札南贷款。
| 2 | ||||
| 定义 | ||
发展 包括从头开始的施工。一旦物业投入使用，新完成的开发项目被视为完全运作。
EBITDAre, Adjusted EBITDAre, and Fixed Charge Coverage Adjusted EBITDAre EBITDAre, or EBITDA for Real Estate, is a supplemental performance measure defined by the National Association of Real Estate Investment Trusts (“Nareit”) and intended for real estate companies. It represents earnings before interest expense, income taxes, depreciation and amortization, gains or losses from sales of depreciable property (including gains or losses on change in control), and impairment charges (recoveries) related to depreciable property. Adjusted EBITDAre is defined as EBITDAre excluding other impairments (recoveries) and other losses (gains), transaction and merger-related items, prepayment costs (benefits) associated with early retirement or payment of debt, restructuring and severance-related charges, litigation costs (recoveries), casualty-related charges (recoveries), stock-based compensation amortization expense, and foreign currency remeasurement losses (gains), adjusted to reflect the impact of transactions that closed during the period as if the transactions were completed at the beginning of the period. Fixed Charge Coverage Adjusted EBITDAre is defined as Adjusted EBITDAre excluding the adjustment to reflect the impact of transactions that closed during the period as if the transactions were completed at the beginning of the period. EBITDAre, Adjusted EBITDAre, and Fixed Charge Coverage Adjusted EBITDAre include our pro rata share of our unconsolidated JVs presented on the same basis. We consider EBITDAre and Adjusted EBITDAre important supplemental measures to net income (loss) because they provide an additional manner in which to evaluate our operating performance and serve as additional indicators of our ability to service our debt obligations. Net income (loss) is the most directly comparable U.S. generally accepted accounting principles (“GAAP”) measure to EBITDAre and Adjusted EBITDAre.
Enterprise Debt Consolidated Debt plus our pro rata share of total debt from our unconsolidated JVs. Enterprise Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share of total debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.
Enterprise Gross Assets Consolidated Gross Assets plus our pro rata share of total gross assets from our unconsolidated JVs, after adding back accumulated depreciation and amortization. Enterprise Gross Assets is a supplemental measure of our financial position, which, when used in conjunction with debt-related measures, enables both management and investors to analyze our leverage and to compare our leverage to that of other companies.
Enterprise Secured Debt Consolidated Secured Debt plus our pro rata share of mortgage debt from our unconsolidated JVs. Enterprise Secured Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share of Enterprise Secured Debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.
Entrance Fees Certain of our CCRC communities have residency agreements which require the resident to pay an upfront entrance fee prior to taking occupancy at the community. For net income, NOI, Adjusted NOI, Nareit FFO, FFO as Adjusted, and AFFO, the non-refundable portion of the entrance fee is recorded as deferred entrance fee revenue and amortized over the estimated stay of the resident based on an actuarial valuation. The refundable portion of a resident’s entrance fee is generally refundable within a certain number of months or days following contract termination or upon the sale of the unit. All refundable amounts due to residents at any time in the future are classified as liabilities.
Financial Leverage Enterprise Debt divided by Enterprise Gross Assets. Financial Leverage is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share information is calculated by applying our actual ownership percentage for the period and excludes debt funded by us to our JVs. Our pro rata share of total debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.
Fixed Charges Total interest expense plus capitalized interest plus preferred stock dividends (if applicable). Fixed Charges also includes our pro rata share of the interest expense plus capitalized interest plus preferred stock dividends (if applicable) of our unconsolidated JVs. Fixed Charges is a supplemental measure of our interest payments on outstanding debt and dividends to preferred stockholders for purposes of presenting Fixed Charge Coverage and Adjusted Fixed Charge Coverage. Fixed Charges is subject to limitations and qualifications, as, among other things, it does not include all contractual obligations.
Funds From Operations (“Nareit FFO”) and FFO as Adjusted Nareit FFO. Funds from Operations (“FFO”), as defined by the National Association of Real Estate Investment Trusts (“Nareit”), is net income (loss) applicable to common shares (computed in accordance with GAAP), excluding gains or losses from sales of depreciable property, including any current and deferred taxes directly associated with sales of depreciable property, impairments of, or related to, depreciable real estate, plus real estate-related depreciation and amortization, and adjustments to compute our share of Nareit FFO from joint ventures. Adjustments for joint ventures are calculated to reflect our pro rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of Nareit FFO for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. For consolidated joint ventures in which we do not own 100%, we reflect our share of the equity by adjusting our Nareit FFO to remove the third-party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods. Our pro rata share information is prepared on a basis consistent with the comparable consolidated amounts, is intended to reflect our proportionate economic interest in the operating results of properties in our portfolio and is calculated by applying our actual ownership percentage for the period. We do not control the unconsolidated joint ventures, and the pro rata presentations of reconciling items included in Nareit FFO do not represent our legal claim to such items. The joint venture members or partners are entitled to profit or loss allocations and distributions of cash flows according to the joint venture agreements, which provide for such allocations generally according to their invested capital.
The presentation of pro rata information has limitations, which include, but are not limited to, the following: (i) the amounts shown on the individual line items were derived by applying our overall economic ownership interest percentage determined when applying the equity method of accounting and do not necessarily represent our legal claim to the assets and liabilities, or the revenues and expenses and (ii) other companies in our industry may calculate their pro rata interest differently, limiting the usefulness as a comparative measure. Because of these limitations, the pro rata financial information should not be considered independently or as a substitute for our financial statements as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP financial statements, using the pro rata financial information as a supplement.
| 3 | ||||
| Definitions | ||
We believe Nareit FFO applicable to common shares and diluted FFO applicable to common shares are important supplemental non-GAAP measures of operating performance for a REIT. Because the historical cost accounting convention used for real estate assets utilizes straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. Since real estate values instead have historically risen and fallen with market conditions, presentations of operating results for a REIT that use historical cost accounting for depreciation could be less informative. The term Nareit FFO was designed by the REIT industry to address this issue.
Nareit FFO does not represent cash generated from operating activities in accordance with GAAP, is not necessarily indicative of cash available to fund cash needs and should not be considered an alternative to net income (loss). We compute Nareit FFO in accordance with the current Nareit definition; however, other REITs may report Nareit FFO differently or have a different interpretation of the current Nareit definition from ours. For a reconciliation of net income (loss) to Nareit FFO and other relevant disclosures, refer to “Non-GAAP Financial Measures Reconciliations” below.
FFO as Adjusted. In addition, we present Nareit FFO on an adjusted basis before the impact of non-comparable items including, but not limited to, transaction and merger-related items, other impairments (recoveries) and other losses (gains), restructuring and severance-related charges, prepayment costs (benefits) associated with early retirement or payment of debt, litigation costs (recoveries), casualty-related charges (recoveries), deferred tax asset valuation allowances, and changes in tax legislation (“FFO as Adjusted”). These adjustments are net of tax, when applicable, and are reflective of our share from our joint ventures. Adjustments for joint ventures are calculated to reflect our pro rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of FFO as Adjusted for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. We reflect our share for consolidated joint ventures in which we do not own 100% of the equity by adjusting our FFO as Adjusted to remove the third-party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods. See “Nareit FFO” above for further disclosures regarding our use of pro rata share information and its limitations. Transaction and merger-related items include transaction expenses and gains/charges incurred as a result of mergers and acquisitions and lease amendment or termination activities. Prepayment costs (benefits) associated with early retirement of debt include the write-off of unamortized deferred financing fees, or additional costs, expenses, discounts, make-whole payments, penalties or premiums incurred as a result of early retirement or payment of debt. Other impairments (recoveries) and other losses (gains) include interest income associated with early and partial repayments of loans receivable and other losses or gains associated with non-depreciable assets including goodwill, undeveloped land parcels, and loans receivable. Management believes that FFO as Adjusted provides a meaningful supplemental measurement of our FFO run-rate and is frequently used by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. At the same time that Nareit created and defined its FFO measure for the REIT industry, it also recognized that “management of each of its member companies has the responsibility and authority to publish financial information that it regards as useful to the financial community.” We believe stockholders, potential investors, and financial analysts who review our operating performance are best served by an FFO run-rate earnings measure that includes certain other adjustments to net income (loss), in addition to adjustments made to arrive at the Nareit defined measure of FFO. FFO as Adjusted is used by management in analyzing our business and the performance of our properties and we believe it is important that stockholders, potential investors, and financial analysts understand this measure used by management. We use FFO as Adjusted to: (i) evaluate our performance in comparison with expected results and results of previous periods, relative to resource allocation decisions, (ii) evaluate the performance of our management, (iii) budget and forecast future results to assist in the allocation of resources, (iv) assess our performance as compared with similar real estate companies and the industry in general, and (v) evaluate how a specific potential investment will impact our future results. Other REITs or real estate companies may use different methodologies for calculating an adjusted FFO measure, and accordingly, our FFO as Adjusted may not be comparable to those reported by other REITs.
Investment and Portfolio Investment Represents: (i) the carrying amount of real estate assets and intangibles, after adding back accumulated depreciation and amortization and (ii) the carrying amount of Debt Investments. Portfolio Investment also includes our pro rata share of the real estate assets and intangibles held in our unconsolidated JVs, presented on the same basis as Investment, and excludes noncontrolling interests' pro rata share of the real estate assets and intangibles held in our consolidated JVs, presented on the same basis. Investment and Portfolio Investment include land held for development.
Merger-Combined Same-Store (“SS”) Merger-Combined Same-Store Cash (Adjusted) NOI includes legacy Physicians Realty Trust properties that met the same-store criteria as if they were owned by the Company for the full analysis period. This information allows our investors, analysts, and Company management to evaluate the performance of our property portfolio under a consistent population by eliminating changes in the composition of our portfolio of properties, excluding properties within the other non-reportable segments. We include properties from our consolidated portfolio, as well as properties owned by our unconsolidated joint ventures in Merger-Combined Same-Store Adjusted NOI (see Cash (Adjusted) NOI definitions above for further discussion regarding our use of pro-rata share information and its limitations). Properties are included in Merger-Combined Same-Store once they are fully operating for the entirety of the comparative periods presented. A property is removed from Merger-Combined Same-Store when it is classified as held for sale, sold, placed into redevelopment, experiences a casualty event that significantly impacts operations, or a significant tenant relocates from a Merger-Combined Same-Store property to a Merger-Combined non Same-Store property and that change results in a corresponding increase in revenue. We do not report Merger-Combined Same-Store metrics for our other non-reportable segments.
Management believes that continued reporting of the same-store portfolio for only pre-merger Healthpeak Properties, Inc. offers minimal value to investors who are seeking to understand the operating performance and growth potential of the combined company. The Company was provided access to the underlying financial statements of legacy Physicians Realty Trust (which financial statements have been audited or, in the case of interim periods, reviewed) and other detailed information about each property, such as the acquisition date. Based on this available information, the Company was able to consistently apply its same-store definition across the combined portfolio. As a result of the Merger, approximately 98% of the combined portfolio is represented in the Merger-Combined Same-Store presentation for the outpatient medical segment.
Merger-Combined Same-Store Cash (Adjusted) NOI Merger-Combined Same-Store Cash (Adjusted) NOI is Merger-Combined Same-Store Cash Real Estate Revenues less Merger-Combined Same-Store Cash Operating Expenses.
Merger-Combined Same-Store Cash Operating Expenses Merger-Combined Same-Store Cash Operating Expenses are non-GAAP supplemental measures. Merger-Combined Same-Store Cash Operating Expenses represent property level operating expenses (which exclude transition costs) and exclude certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis. Merger-Combined Same-Store Cash Operating Expenses include consolidated operating expenses plus the Company's pro rata share of
| 4 | ||||
| Definitions | ||
operating expenses from its unconsolidated JVs less noncontrolling interests' pro rata share of operating expenses from consolidated JVs. Merger-Combined Same-Store Cash Operating Expenses eliminates the effects of straight-line rents, lease termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee expense.
Merger-Combined Same-Store Cash Real Estate Revenues Merger-Combined Same-Store Cash Real Estate Revenues are non-GAAP supplemental measures. Merger-Combined Same-Store Cash Real Estate Revenues include rental related revenues, resident fees and services and exclude amortization of deferred revenue from tenant-funded improvements. Merger-Combined Same-Store Cash Real Estate Revenues include the Company's pro rata share from unconsolidated JVs presented on the same basis and exclude noncontrolling interests' pro rata share from consolidated JVs presented on the same basis. Merger-Combined Same-store Cash Real Estate Revenues eliminates the effects of straight-line rents, amortization of market lease intangibles, lease termination fees, and the impact of deferred community fee income.
Net Debt Enterprise Debt less the carrying amount of cash and cash equivalents, restricted cash, and expected net proceeds from the future settlement of shares issued through our equity forward contracts, as reported in our consolidated financial statements and our pro rata share of cash and cash equivalents and restricted cash from our unconsolidated JVs. Consolidated Debt is the most directly comparable GAAP measure to Net Debt. Net Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies.
Net Debt to Adjusted EBITDAre Net Debt divided by Adjusted EBITDAre is a supplemental measure of our ability to decrease our debt. Because we may not be able to use our cash to reduce our debt on a dollar-for-dollar basis, this measure may have material limitations.
Portfolio Adjusted NOI Portfolio Adjusted NOI is Portfolio Cash Real Estate Revenues less Portfolio Cash Operating Expenses.
Portfolio Cash Operating Expenses Portfolio Cash Operating Expenses are non-GAAP supplemental measures. Portfolio Cash Operating Expenses represent property level operating expenses (which exclude transition costs). Portfolio Cash Operating Expenses include consolidated operating expenses plus the Company's pro rata share of operating expenses from its unconsolidated JVs less noncontrolling interests' pro rata share of operating expenses from consolidated JVs. Portfolio Cash Operating Expenses eliminates the effects of straight-line rents, lease termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee expense.
Portfolio Cash Real Estate Revenues Portfolio Cash Real Estate Revenues are non-GAAP supplemental measures. Portfolio Cash Real Estate Revenues include rental related revenues, resident fees and services, and government grant income which is included in Other income (expense), net in our Consolidated Statement of Operations. Portfolio Cash Real Estate Revenues include the Company's pro rata share from unconsolidated JVs presented on the same basis and exclude noncontrolling interests' pro rata share from consolidated JVs presented on the same basis. Portfolio Cash Real Estate Revenues eliminates the effects of straight-line rents, amortization of market lease intangibles, lease termination fees, and the impact of deferred community fee income.
Portfolio Income Cash (Adjusted) NOI plus interest income plus our pro rata share of Cash (Adjusted) NOI from our unconsolidated JVs less noncontrolling interests' pro rata share of Cash (Adjusted) NOI from consolidated JVs. Management believes that Portfolio Income is an important supplemental measure because it provides relevant and useful information regarding our performance; specifically, it is a measure of our property level profitability of the Company inclusive of interest income. Management believes that net income (loss) is the most directly comparable GAAP measure to Portfolio Income. Portfolio Income should not be viewed as an alternative measure of operating performance to net income (loss) as defined by GAAP since it does not reflect various excluded items.
Projected Stabilized Cash Yield Projected Cash (Adjusted) NOI at stabilization divided by the expected total development costs. Management considers Projected Stabilized Yield a useful metric for investors as it helps provide context to the expected effects that development projects will have on the Company’s future performance once stabilized.
Redevelopment Properties that incur major capital expenditures to significantly improve, change the use, or reposition the property pursuant to a formal redevelopment plan. Newly completed redevelopments, are considered fully operating once the property is placed in service. Redevelopment costs include only the incremental costs for the project.
REVPOR The 3-month average Cash Real Estate Revenues per occupied unit for the most recent period available. REVPOR excludes newly completed assets under lease-up, assets sold, acquired or converted to a new operating structure during the relevant period, assets in redevelopment, assets that are held for sale, and assets that experienced a casualty event that significantly impacted operations. REVPOR cannot be derived from the information presented for the Other portfolio as units reflect 100% of the unit capacities for unconsolidated JVs and revenue is at the Company's pro rata share. All facility occupancy data was derived solely from information provided by operators without independent verification by us. REVPOR relates to our Other non-reportable segment. REVPOR is a metric used to evaluate the revenue-generating capacity and profit potential of our other assets independent of fluctuating occupancy rates. It is also used in comparison against industry and competitor statistics, if known, to evaluate the quality of our other assets.
REVPOR CCRC The 3-month average Cash Real Estate Revenues per occupied unit excluding Cash NREFs for the most recent period available. REVPOR CCRC excludes newly completed assets under lease-up, assets sold, or acquired during the relevant period, assets in redevelopment, assets that are held for sale, and assets that experienced a casualty event that significantly impacted operations. All facility occupancy data was derived solely from information provided by operators without independent verification by us. REVPOR CCRC is a metric used to evaluate the revenue-generating capacity and profit potential of our CCRC assets independent of fluctuating occupancy rates. It is also used in comparison against industry and competitor statistics, if known, to evaluate the quality of our CCRC assets.
RIDEA A structure whereby a taxable REIT subsidiary is permitted to rent a healthcare facility from its parent REIT and hire an independent contractor to operate the facility.
Secured Debt Ratio Enterprise Secured Debt divided by Enterprise Gross Assets. Secured Debt Ratio is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share information is calculated by applying our actual ownership percentage for the period and excludes debt funded by us to our JVs. Our pro rata share of Total Secured Debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.
| 5 | ||||
| Definitions | ||
Segments The Company’s diverse portfolio is comprised of investments in the following reportable healthcare segments: (i) outpatient medical; (ii) lab; and (iii) continuing care retirement community (“CCRC”).
联营企业（"合资企业"）的份额 非控股权的按比例份额信息是通过应用非控股权在期间的实际持有百分比而编制的，旨在反映非控股权在我们投资组合中资产的财务状况和经营业绩中的比例经济利益。
非合并合资企业（"JVs"）的份额 我们的比例份额信息是通过应用我们在该期间的实际持股百分比来准备的，旨在反映我们在投资组合中物业的财务状况和运营结果中的比例经济利益。对于租赁信息不可用的情况，将排除某些非合并合资企业的租赁统计。
| 6 | ||||
| 协调 | ||
| 所有基金类型资金运营资产 | ||
以千为单位，每股数据除外
| 三个月之内结束 2020年9月30日 | 九个月结束 2020年9月30日 | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| 适用于普通股的净收益（亏损） | $ | 85,675 | $ | 64,048 | $ | 237,985 | $ | 233,497 | |||||||||||||||
| 房地产业相关的折旧和摊销 | 280,019 | 184,559 | 782,736 | 561,357 | |||||||||||||||||||
| Healthpeak在未纳入合并范围的合资企业中房地产相关的折旧和摊销 | 12,127 | 6,190 | 32,520 | 18,076 | |||||||||||||||||||
| 非控股股权对房地产相关的折旧和摊销的份额 | (4,534) | (4,571) | (13,705) | (14,042) | |||||||||||||||||||
| 房地产业折旧房地产的出售损益净额 | (62,325) | — | (187,624) | (86,463) | |||||||||||||||||||
| 非控股权益在房地产业折旧房地产的出售损益中的份额 | — | — | — | 11,546 | |||||||||||||||||||
控制权变更的损益净额(1) | 430 | — | (77,548) | (234) | |||||||||||||||||||
与房地产处置相关的税款(2) | (145) | — | 11,512 | — | |||||||||||||||||||
| 适用于普通股的Nareit FFO | 311,247 | 250,226 | 785,876 | 723,737 | |||||||||||||||||||
| 拆分稀释可转换单位和其他支付 | 4,577 | 2,340 | 11,670 | 7,027 | |||||||||||||||||||
| 适用于普通股的稀释后Nareit FFO | $ | 315,824 | $ | 252,566 | $ | 797,546 | $ | 730,764 | |||||||||||||||
| 加权平均流通股数 - 稀释后Nareit FFO | 714,715 | 554,614 | 681,128 | 554,535 | |||||||||||||||||||
| 对Nareit FFO调整的影响: | |||||||||||||||||||||||
交易和并购相关项目(3) | $ | 2,725 | $ | 49 | $ | 108,923 | $ | 2,993 | |||||||||||||||
其他减值（回收）和其他损失（收益），净额(4) | 441 | (602) | 11,741 | 557 | |||||||||||||||||||
| 重组和与裁员相关的费用 | — | — | — | 1,368 | |||||||||||||||||||
灾害相关费用（收入），净额(5) | 1,792 | (367) | 588 | (610) | |||||||||||||||||||
| 调整总计 | $ | 4,958 | $ | (920) | $ | 121,252 | $ | 4,308 | |||||||||||||||
| 适用于普通股的调整后 FFO | $ | 316,205 | $ | 249,306 | $ | 907,128 | $ | 728,045 | |||||||||||||||
| 转股单位和其他可稀释单位的分发 | 4,571 | 2,341 | 11,537 | 7,022 | |||||||||||||||||||
| 调整后的摊薄基金运营所适用的普通股 | $ | 320,776 | $ | 251,647 | $ | 918,665 | $ | 735,067 | |||||||||||||||
| 摊薄后的调整基金运营所适用的加权平均股份 | 714,715 | 554,614 | 681,128 | 554,535 | |||||||||||||||||||
| 调整后的基金运营所适用的普通股 | $ | 316,205 | $ | 249,306 | $ | 907,128 | $ | 728,045 | |||||||||||||||
| 股票补偿摊销费用 | 3,755 | 3,434 | 11,935 | 10,966 | |||||||||||||||||||
| 延期融资成本和债务折扣（溢价）摊销 | 7,408 | 3,054 | 19,247 | 8,828 | |||||||||||||||||||
直线租金(6) | (10,346) | (7,279) | (32,891) | (12,710) | |||||||||||||||||||
| AFFO资本支出 | (23,510) | (24,031) | (76,744) | (66,264) | |||||||||||||||||||
| 延迟所得税 | 585 | (430) | 2,330 | (933) | |||||||||||||||||||
| 以上（以下）市场租赁无形资产的摊销，净额 | (7,887) | (5,626) | (23,325) | (20,267) | |||||||||||||||||||
| 其他经调整自由现金流（AFFO）项目 | (1,277) | (1,123) | (4,947) | (1,852) | |||||||||||||||||||
| 适用于普通股的AFFO | 284,933 | 217,305 | 802,733 | 645,813 | |||||||||||||||||||
| 可转换股份和其他稀释券的分配 | 4,576 | 2,340 | 11,671 | 7,026 | |||||||||||||||||||
| 用于普通股的摊薄AFFO | $ | 289,509 | $ | 219,645 | $ | 814,404 | $ | 652,839 | |||||||||||||||
| 加权平均股份数-摊薄AFFO | 714,715 | 554,614 | 681,128 | 554,535 | |||||||||||||||||||
| 7 | ||||
| 协调 | ||
| 所有基金类型资金运营资产 | ||||||||||||||
以千为单位，每股数据除外
| 三个月之内结束 2020年9月30日 | 九个月结束 2020年9月30日 | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| 稀释每股收益 | $ | 0.12 | $ | 0.12 | $ | 0.36 | $ | 0.43 | |||||||||||||||
| 折旧和摊销 | 0.41 | 0.34 | 1.18 | 1.03 | |||||||||||||||||||
| 固定资产房地产业售卖盈亏，净额 | (0.09) | — | (0.28) | (0.14) | |||||||||||||||||||
控制权变动盈亏，净额(1) | 0.00 | — | (0.11) | 0.00 | |||||||||||||||||||
与房地产处置相关的税收(2) | 0.00 | — | 0.02 | — | |||||||||||||||||||
| 每普通股摊薄后的Nareit FFO | $ | 0.44 | $ | 0.46 | $ | 1.17 | $ | 1.32 | |||||||||||||||
交易和并购相关项目(3) | 0.01 | 0.00 | 0.16 | 0.01 | |||||||||||||||||||
其他减值损失（收益）和其他损失（收益），净额(4) | 0.00 | (0.01) | 0.02 | 0.00 | |||||||||||||||||||
| 重组和与裁员有关的费用 | — | — | — | 0.00 | |||||||||||||||||||
灾害相关费用（收入），净额(5) | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||||||||
| 每普通股调整后的摊薄FFO | $ | 0.45 | $ | 0.45 | $ | 1.35 | $ | 1.33 | |||||||||||||||
| 股权报酬摊销支出 | 0.01 | 0.01 | 0.02 | 0.03 | |||||||||||||||||||
| 推迟融资成本和债务折扣（溢价）的摊销 | 0.01 | 0.01 | 0.03 | 0.02 | |||||||||||||||||||
直线租金(6) | (0.02) | (0.01) | (0.05) | (0.02) | |||||||||||||||||||
| 调整后基金可分配现金净收益资本支出 | (0.03) | (0.05) | (0.11) | (0.14) | |||||||||||||||||||
| 延迟所得税 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||||||||
| 市场租赁（借准）无形资产摊销净额 | (0.01) | (0.01) | (0.03) | (0.04) | |||||||||||||||||||
| 其他调整后基金可分配现金净收益 | 0.00 | 0.00 | (0.01) | 0.00 | |||||||||||||||||||
| 每股稀释后基金可分配现金净收益 | $ | 0.41 | $ | 0.40 | $ | 1.20 | $ | 1.18 | |||||||||||||||
______________________________________
(1)2024年9月30日结束的九个月中，涉及在加利福尼亚圣迭戈出售两栋实验室大楼的65%权益变动所产生的收益。此变动所产生的收益已记入综合经营利润表中的其他收入（费用），净额。
(2)2024年9月30日结束的九个月包括与在加利福尼亚圣迭戈出售两栋实验楼的65%股权相关的非现金所得税支出。
(3)2024年9月30日结束的三个月和九个月包括与合并相关的成本，主要由咨询、法律、会计、税务、合并后割离和股票补偿支出以及在该期间与physicians realty trust进行业务合并的其他成本组成。这些成本部分被400万美元的终止费用收入抵消，分别为2024年9月30日结束的三个月和九个月，与Graphite Bio, Inc.相关，该公司于2024年3月后与LENZ Therapeutics, Inc.合并，此后将租赁条款修改以加速到2024年12月到期。其余的400万美元终止费用收入将在2024年第四季度确认。终止费用收入包括在综合经营报告的租赁和相关收入中，但被排除在Healthpeak对投资组合现金房地产收入和调整后FFO的定义之外。
(4)2024年9月30日和2023年第三季度包括在运营综合账户中的预期贷款损失储备和（收益），以及贷款损失储备（收益）和净损失。
(5)与伤亡相关的费用（收回），均在综合利润（损失），及在综合利益（损失）账户的未合并机动合营企业中确认。
(6)2023年9月30日结束的九个月包括一笔900万美元在Sorrento Therapeutics, Inc.推行根据美国破产法第11章自愿重组程序直线租金应收账款的减值。该项活动反映在合并利润表中，作为租赁和相关收入的减少。
| 8 | ||||
| 协调 | ||
2024年度指导原则(1) | ||||||||||||||
每股数据
| 2024年指导范围 | |||||||||||
| 收盘最低价 | 高中 | ||||||||||
| 稀释每股收益 | $ | 0.40 | $ | 0.42 | |||||||
| 房地产业相关的折旧和摊销 | 1.55 | 1.55 | |||||||||
| Healthpeak在未合并联营企业中与房地产相关的折旧和摊销份额 | 0.07 | 0.07 | |||||||||
| 非控股权益在房地产相关的折旧和摊销中的份额 | (0.03) | (0.03) | |||||||||
| 房地产业折旧房地产的出售损益净额 | (0.28) | (0.28) | |||||||||
| 控制权变更的损益净额 | (0.12) | (0.12) | |||||||||
| 与房地产处置相关的税款 | 0.02 | 0.02 | |||||||||
| 每普通股摊薄后的Nareit FFO | $ | 1.61 | $ | 1.63 | |||||||
| 交易和并购相关项目 | $ | 0.16 | $ | 0.16 | |||||||
| 其他减值（回收）和其他损失（收益），净额 | 0.02 | 0.02 | |||||||||
| 每普通股调整后的摊薄FFO | $ | 1.79 | $ | 1.81 | |||||||
| 股票补偿摊销费用 | $ | 0.03 | $ | 0.03 | |||||||
| 延期融资成本和债务折扣（溢价）摊销 | 0.05 | 0.05 | |||||||||
| 直线租金 | (0.07) | (0.07) | |||||||||
| AFFO资本支出 | (0.18) | (0.18) | |||||||||
| 以上（以下）市场租赁无形资产的摊销，净额 | (0.05) | (0.05) | |||||||||
| 其他经调整自由现金流（AFFO）项目 | (0.01) | (0.01) | |||||||||
| 每股稀释后基金可分配现金净收益 | $ | 1.56 | $ | 1.58 | |||||||
______________________________________
(1)上述预测反映了管理层截至2024年10月24日对当前和未来市场状况的看法，包括关于租金率、入住率、开发项目以及我们于2024年10月24日发布的营收新闻稿中提到的事件对盈利的影响的假设。然而，这些预测不包括未宣布的未来交易的影响，除本文所述外。我们的实际结果可能与上述预测有实质性差异。除非法律另有规定，管理层不承担更新上述预测的任何义务，并在此声明不承担因新信息、新发展或未来事件而更新上述预测的任何义务。
| 9 | ||||
| 协调 | ||
2024年度指导原则(1) | ||||||||||||||
单位为百万
预计2024年（低）
| 总投资组合 | |||||
| 净利润 | $ | 295 | |||
| 房地产业相关的折旧和摊销 | 1,050 | ||||
| 房地产业折旧房地产的出售损益净额 | (188) | ||||
| 其他减值（回收）和其他损失（收益），净额 | 11 | ||||
| 其他收入、成本和费用调整为现金（调整后）净营收 | 314 | ||||
| 现金（调整后）净营收 | $ | 1,482 | |||
| 合并前的遗留医师房地产信托调整后的净营收 | 53 | ||||
| 合并后的非同店调整后净营业收入 | (183) | ||||
合并后的总同店现金（调整后）净营业收入(2) | $ | 1,352 | |||
预计2024年（高）
| 总投资组合 | |||||
| 净利润 | $ | 309 | |||
| 房地产业相关的折旧和摊销 | 1,050 | ||||
| 房地产业折旧房地产的出售损益净额 | (188) | ||||
| 其他减值（回收）和其他损失（收益），净额 | 11 | ||||
| 现金（调整后）净营业收入的其他收入、成本和费用调整 | 314 | ||||
| 现金（调整后）净营业收入 | $ | 1,496 | |||
| 合并前的传统physicians realty trust调整后的净营业收入 | 53 | ||||
| 合并后的非同店调整净营业收入 | (184) | ||||
合并后的总同店现金（调整后）净营业收入(2) | $ | 1,365 | |||
截至2023年12月31日的年度报告
| 总投资组合 | |||||
| 净利润 | $ | 335 | |||
| 房地产业相关的折旧和摊销 | 750 | ||||
| 房地产业折旧房地产的出售损益净额 | (86) | ||||
| 其他减值（回收）和其他损失（收益），净额 | (6) | ||||
| 其他收入、成本和费用调整为现金（调整后）净营收 | 212 | ||||
| 现金（调整后）净营收 | $ | 1,205 | |||
| 合并前的遗留医师房地产信托调整后的净营收 | 312 | ||||
| 合并后的非同店调整后净营业收入 | (212) | ||||
合并后的总同店现金（调整后）净营业收入(2) | $ | 1,306 | |||
持续
| 10 | ||||
| 协调 | ||
2024年度指导原则(1) | ||||||||||||||
单位为百万
2024财年全年预期并购-合并现金同店销售额
| 收盘最低价 | 3.50 | % | |||
| 高 | 4.50 | % | |||
______________________________________
(1)前述的预测反映了管理层截至2024年10月24日对当前和未来市场状况的看法，其中包括对租金率、入住率、开发项目以及我们在2024年10月24日发布的盈利新闻稿中提到的事件对收益的影响的假设。然而，这些预测不反映未宣布的未来交易的影响，除非在此处描述。我们的实际结果可能与上述预测有实质差异。除非法律另有规定，管理层不承担任何义务，并在此声明不会更新前述任何预测，因为有新信息或新的或未来的进展。由于四舍五入而可能无法核对或重新计算。
(2)总并购-合并同店现金净营业收入（调整后）包括符合同店定义的传统医师地产信托物业的经营结果，就像它们在所呈现的整个时段内由公司拥有一样。
| 11 | ||||
| 协调 | ||
| 企业总资产 | ||||||||||||||
以千为单位
| 2024年9月30日 | |||||
合并总资产(1) | $ | 19,969,766 | |||
| 对非合并合资企业的投资和预付款 | (931,844) | ||||
| 房地产累计折旧和摊销 | 3,925,375 | ||||
| 房地产无形资产累计摊销 | 597,460 | ||||
| 合并总资产 | $ | 23,560,757 | |||
| Healthpeak在未纳入合并范围的合资企业总资产中所占份额 | 1,373,382 | ||||
| 企业总资产 | $ | 24,934,139 | |||
______________________________________
(1)合并总资产是指2024年9月30日财务报表中的总资产，在2024年9月30日季度收益发布和补充报告的第8页呈现。
| 投资组合投资 | ||
以千为单位
| 2024年9月30日 | |||||||||||||||||||||||||||||
| 门诊 医疗 | 实验室 | CCRC | 其他 | 总费用 | |||||||||||||||||||||||||
| 净房地产 | $ | 7,085,319 | $ | 7,150,002 | $ | 1,657,091 | $ | — | $ | 15,892,412 | |||||||||||||||||||
| 无形资产, 净额 | 749,960 | 60,193 | 88,226 | — | 898,379 | ||||||||||||||||||||||||
| 房地产累计折旧和摊销 | 1,929,183 | 1,577,724 | 418,468 | — | 3,925,375 | ||||||||||||||||||||||||
| 房地产无形资产累计摊销 | 278,110 | 70,898 | 248,452 | — | 597,460 | ||||||||||||||||||||||||
| Healthpeak对未纳入合并范围的联营企业毛房地产资产的份额 | 235,870 | 568,902 | — | 474,184 | 1,278,956 | ||||||||||||||||||||||||
| 完全折旧和摊销的房地产和无形资产 | 752,477 | 572,089 | 25,369 | — | 1,349,935 | ||||||||||||||||||||||||
| 租赁佣金和其他 | 177,616 | 97,482 | — | — | 275,098 | ||||||||||||||||||||||||
| 债务投资 | — | — | — | 631,164 | 631,164 | ||||||||||||||||||||||||
| 房地产无形负债，总额 | (241,895) | (190,922) | — | — | (432,817) | ||||||||||||||||||||||||
| 非控股利益在合并联营创业公司房地产及相关无形资产中的份额 | (418,228) | — | — | — | (418,228) | ||||||||||||||||||||||||
| 投资组合 | $ | 10,548,412 | $ | 9,906,368 | $ | 2,437,606 | $ | 1,105,348 | $ | 23,997,734 | |||||||||||||||||||
| 12 | ||||
| 协调 | ||
| 收入 | ||
以千为单位
| 三个月之内结束 | ||||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度报告 2023 | 截至12月31日公允价值 2023 | 3月31号 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| 门诊医疗 | $ | 191,016 | $ | 188,835 | $ | 238,272 | $ | 332,515 | $ | 317,659 | ||||||||||||||||||||||
| 实验室 | 226,059 | 223,497 | 223,761 | 214,266 | 225,592 | |||||||||||||||||||||||||||
| CCRC | 133,808 | 136,341 | 138,776 | 140,891 | 142,845 | |||||||||||||||||||||||||||
| 其他 | 5,360 | 4,979 | 5,059 | 6,878 | 13,126 | |||||||||||||||||||||||||||
| 企业非分割 | — | — | 692 | 954 | 1,175 | |||||||||||||||||||||||||||
| 总收入 | $ | 556,243 | $ | 553,652 | $ | 606,560 | $ | 695,504 | $ | 700,397 | ||||||||||||||||||||||
| 门诊医疗 | — | — | — | — | — | |||||||||||||||||||||||||||
| 实验室 | — | — | — | — | — | |||||||||||||||||||||||||||
| CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | (5,360) | (4,979) | (5,059) | (6,878) | (13,126) | |||||||||||||||||||||||||||
| 公司非分部 | — | — | (692) | (954) | (1,175) | |||||||||||||||||||||||||||
| 减：利息收入和其他 | $ | (5,360) | $ | (4,979) | $ | (5,751) | $ | (7,832) | $ | (14,301) | ||||||||||||||||||||||
| 门诊医疗 | 746 | 788 | 2,739 | 6,903 | 7,065 | |||||||||||||||||||||||||||
| 实验室 | 2,425 | 3,406 | 4,861 | 4,301 | 5,242 | |||||||||||||||||||||||||||
| CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | 20,572 | 21,247 | 21,533 | 21,378 | 21,886 | |||||||||||||||||||||||||||
| 公司非分部 | — | — | — | — | — | |||||||||||||||||||||||||||
| Healthpeak的非合并合资房地产业收入份额 | $ | 23,743 | $ | 25,441 | $ | 29,133 | $ | 32,582 | $ | 34,193 | ||||||||||||||||||||||
| 门诊医疗 | — | — | — | — | — | |||||||||||||||||||||||||||
| 实验室 | — | — | — | — | — | |||||||||||||||||||||||||||
| 退休社区连续护理中心（CCRC） | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | — | 1 | — | — | — | |||||||||||||||||||||||||||
| 企业非分部 | — | — | — | — | — | |||||||||||||||||||||||||||
| Healthpeak对未纳入合并的联营创业公司政府补助收入的份额 | $ | — | $ | 1 | $ | — | $ | — | $ | — | ||||||||||||||||||||||
| 门诊医疗 | (8,735) | (8,710) | (8,876) | (9,341) | (9,734) | |||||||||||||||||||||||||||
| 实验室 | (154) | (171) | (163) | (33) | — | |||||||||||||||||||||||||||
| CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | — | — | — | — | — | |||||||||||||||||||||||||||
| 企业非区段 | — | — | — | — | — | |||||||||||||||||||||||||||
| 非控股利益份额占合并合资房地产业收入 | $ | (8,889) | $ | (8,881) | $ | (9,039) | $ | (9,374) | $ | (9,734) | ||||||||||||||||||||||
持续
| 13 | ||||
| 协调 | ||
| 收入 | ||
以千为单位
| 三个月之内结束 | ||||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度报告 2023 | 截至12月31日公允价值 2023 | 3月31号 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| 门诊医疗 | $ | (4,223) | $ | (3,612) | $ | (7,011) | $ | (12,101) | $ | (12,761) | ||||||||||||||||||||||
| 实验室 | (9,477) | (10,296) | (21,127) | (12,988) | (16,647) | |||||||||||||||||||||||||||
| CCRC | — | (1) | 1 | (1) | — | |||||||||||||||||||||||||||
| 其他 | (5) | (81) | (56) | (18) | (71) | |||||||||||||||||||||||||||
| 企业非区段 | — | — | — | — | — | |||||||||||||||||||||||||||
| 房地产业收入的非现金调整 | $ | (13,705) | $ | (13,990) | $ | (28,193) | $ | (25,108) | $ | (29,479) | ||||||||||||||||||||||
| 门诊医疗 | 178,804 | 177,301 | 225,124 | 317,976 | 302,229 | |||||||||||||||||||||||||||
| 实验室 | 218,854 | 216,436 | 207,332 | 205,546 | 214,187 | |||||||||||||||||||||||||||
| CCRC | 133,808 | 136,340 | 138,777 | 140,890 | 142,845 | |||||||||||||||||||||||||||
| 其他 | 20,567 | 21,167 | 21,477 | 21,360 | 21,815 | |||||||||||||||||||||||||||
| 企业非区段 | — | — | — | — | — | |||||||||||||||||||||||||||
投资组合现金房地产营业收入(1) | $ | 552,033 | $ | 551,244 | $ | 592,710 | $ | 685,772 | $ | 681,076 | ||||||||||||||||||||||
| 门诊医疗 | 118,985 | 79,143 | 90,529 | — | — | |||||||||||||||||||||||||||
| 实验室 | — | — | — | — | — | |||||||||||||||||||||||||||
| CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | — | — | — | — | — | |||||||||||||||||||||||||||
| 企业非区段 | — | — | — | — | — | |||||||||||||||||||||||||||
| 合并前遗留的physicians realty trust现金房地产营业收入 | $ | 118,985 | $ | 79,143 | $ | 90,529 | $ | — | $ | — | ||||||||||||||||||||||
| 门诊医疗 | (11,656) | 24,537 | (30,583) | (30,287) | (11,119) | |||||||||||||||||||||||||||
| 实验室 | (44,985) | (44,147) | (33,468) | (28,911) | (32,564) | |||||||||||||||||||||||||||
| CCRC | (205) | (257) | (299) | (306) | (304) | |||||||||||||||||||||||||||
| 其他 | (20,567) | (21,167) | (21,477) | (21,360) | (21,815) | |||||||||||||||||||||||||||
| 企业非区段 | — | — | — | — | — | |||||||||||||||||||||||||||
| 合并后的非自持房地产营业收入 | $ | (77,413) | $ | (41,034) | $ | (85,827) | $ | (80,864) | $ | (65,802) | ||||||||||||||||||||||
| 门诊医疗 | 286,133 | 280,981 | 285,070 | 287,689 | 291,110 | |||||||||||||||||||||||||||
| 实验室 | 173,869 | 172,289 | 173,864 | 176,635 | 181,623 | |||||||||||||||||||||||||||
| CCRC | 133,603 | 136,083 | 138,478 | 140,584 | 142,541 | |||||||||||||||||||||||||||
| 其他 | — | — | — | — | — | |||||||||||||||||||||||||||
| 企业非区段 | — | — | — | — | — | |||||||||||||||||||||||||||
合并后的社保现金房地产业营业收入(3) | $ | 593,605 | $ | 589,353 | $ | 597,412 | $ | 604,908 | $ | 615,274 | ||||||||||||||||||||||
| 14 | ||||
| 协调 | ||
| 研究和开发 | ||
以千为单位
| 三个月之内结束 | ||||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度报告 2023 | 截至12月31日公允价值 2023 | 3月31号 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| 门诊医疗 | $ | 67,693 | $ | 65,691 | $ | 81,268 | $ | 111,702 | $ | 106,484 | ||||||||||||||||||||||
| 实验室 | 60,268 | 56,964 | 56,840 | 56,656 | 64,075 | |||||||||||||||||||||||||||
| CCRC | 104,773 | 105,920 | 105,621 | 105,469 | 109,720 | |||||||||||||||||||||||||||
| 其他 | — | — | — | — | — | |||||||||||||||||||||||||||
| 企业非区段 | — | (4,174) | — | — | — | |||||||||||||||||||||||||||
| 营业费用 | $ | 232,734 | $ | 224,401 | $ | 243,729 | $ | 273,827 | $ | 280,279 | ||||||||||||||||||||||
| 门诊医疗 | 301 | 295 | 1,083 | 2,464 | 2,832 | |||||||||||||||||||||||||||
| 实验室 | 958 | 1,104 | 1,324 | 1,528 | 1,811 | |||||||||||||||||||||||||||
| CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | 15,439 | 15,748 | 16,099 | 15,790 | 16,226 | |||||||||||||||||||||||||||
| 企业非区段 | — | — | — | — | — | |||||||||||||||||||||||||||
| Healthpeak的非合并联营企业营业费用分配 | $ | 16,698 | $ | 17,147 | $ | 18,506 | $ | 19,782 | $ | 20,869 | ||||||||||||||||||||||
| 门诊医疗 | (2,474) | (2,443) | (2,430) | (2,609) | (2,851) | |||||||||||||||||||||||||||
| 实验室 | (33) | (48) | (43) | (9) | — | |||||||||||||||||||||||||||
| CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | — | — | — | — | — | |||||||||||||||||||||||||||
| 企业非区段 | — | — | — | — | — | |||||||||||||||||||||||||||
| 非控股权益的合并联营企业营业费用分配 | $ | (2,507) | $ | (2,491) | $ | (2,473) | $ | (2,618) | $ | (2,851) | ||||||||||||||||||||||
| 门诊医疗 | — | — | — | — | — | |||||||||||||||||||||||||||
| 实验室 | — | — | — | — | — | |||||||||||||||||||||||||||
| CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | — | — | — | — | — | |||||||||||||||||||||||||||
| 企业非区段 | — | (4,174) | — | — | — | |||||||||||||||||||||||||||
| 非资产级别的营业费用 | $ | — | $ | (4,174) | $ | — | $ | — | $ | — | ||||||||||||||||||||||
| 门诊医疗 | (676) | (675) | (884) | (1,671) | (1,741) | |||||||||||||||||||||||||||
| 实验室 | 365 | 612 | 308 | 301 | 253 | |||||||||||||||||||||||||||
| CCRC | — | 940 | 1 | 1,738 | (95) | |||||||||||||||||||||||||||
| 其他 | 22 | (505) | (9) | (244) | 3 | |||||||||||||||||||||||||||
| 企业非区段 | — | — | — | — | — | |||||||||||||||||||||||||||
| 对营业费用的非现金调整 | $ | (289) | $ | 372 | $ | (584) | $ | 124 | $ | (1,580) | ||||||||||||||||||||||
| 门诊医疗 | 64,844 | 62,868 | 79,037 | 109,886 | 104,724 | |||||||||||||||||||||||||||
| 实验室 | 61,558 | 58,632 | 58,429 | 58,476 | 66,139 | |||||||||||||||||||||||||||
| CCRC | 104,773 | 106,860 | 105,622 | 107,207 | 109,625 | |||||||||||||||||||||||||||
| 其他 | 15,461 | 15,243 | 16,090 | 15,546 | 16,229 | |||||||||||||||||||||||||||
| 企业非区段 | — | — | — | — | — | |||||||||||||||||||||||||||
投资组合现金营业费用(2) | $ | 246,636 | $ | 243,603 | $ | 259,178 | $ | 291,115 | $ | 296,717 | ||||||||||||||||||||||
持续
| 15 | ||||
| 协调 | ||
| 研究和开发 | ||
以千为单位
| 三个月之内结束 | ||||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度报告 2023 | 截至12月31日公允价值 2023 | 3月31号 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| 门诊医疗 | $ | 40,172 | $ | 36,580 | $ | 29,131 | $ | — | $ | — | ||||||||||||||||||||||
| 实验室 | — | — | — | — | — | |||||||||||||||||||||||||||
| CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | — | — | — | — | — | |||||||||||||||||||||||||||
| 企业非区段 | — | — | — | — | — | |||||||||||||||||||||||||||
| 合并前的传统医疗房地产信托现金营业费用 | $ | 40,172 | $ | 36,580 | $ | 29,131 | $ | — | $ | — | ||||||||||||||||||||||
| 门诊医疗 | (5,287) | (5,343) | (11,088) | (11,999) | (6,353) | |||||||||||||||||||||||||||
| 实验室 | (8,679) | (8,862) | (7,767) | (7,555) | (8,913) | |||||||||||||||||||||||||||
| CCRC | (537) | (504) | (627) | (440) | (635) | |||||||||||||||||||||||||||
| 其他 | (15,461) | (15,243) | (16,090) | (15,546) | (16,229) | |||||||||||||||||||||||||||
| 企业非区段 | — | — | — | — | — | |||||||||||||||||||||||||||
| 合并后的非SS现金营业费用 | $ | (29,964) | $ | (29,952) | $ | (35,572) | $ | (35,540) | $ | (32,130) | ||||||||||||||||||||||
| 门诊医疗 | 99,729 | 94,105 | 97,080 | 97,887 | 98,371 | |||||||||||||||||||||||||||
| 实验室 | 52,879 | 49,770 | 50,662 | 50,921 | 57,226 | |||||||||||||||||||||||||||
| CCRC | 104,236 | 106,356 | 104,995 | 106,767 | 108,990 | |||||||||||||||||||||||||||
| 其他 | — | — | — | — | — | |||||||||||||||||||||||||||
| 企业非区段 | — | — | — | — | — | |||||||||||||||||||||||||||
合并后的SS现金营业费用(3) | $ | 256,844 | $ | 250,231 | $ | 252,737 | $ | 255,575 | $ | 264,587 | ||||||||||||||||||||||
| 16 | ||||
| 协调 | ||
| 营业收入 | 研究和开发 | |||||||
以千为单位
| 九个月结束 2024年9月30日 | 九个月结束 2024年9月30日 | ||||||||||||||||
| 门诊医疗 | $ | 888,446 | 门诊医疗 | $ | 299,455 | ||||||||||||
| 实验室 | 663,619 | 实验室 | 177,571 | ||||||||||||||
| CCRC | 422,512 | CCRC | 320,809 | ||||||||||||||
| 其他 | 25,063 | 其他 | — | ||||||||||||||
| 企业非区段 | 2,821 | 企业非区段 | — | ||||||||||||||
| 总收入 | $ | 2,002,461 | 营业费用 | $ | 797,835 | ||||||||||||
| 门诊医疗 | — | 门诊医疗 | 6,380 | ||||||||||||||
| 实验室 | — | 实验室 | 4,663 | ||||||||||||||
| CCRC | — | CCRC | — | ||||||||||||||
| 其他 | (25,063) | 其他 | 48,116 | ||||||||||||||
| 企业非区段 | (2,821) | 企业非区段 | — | ||||||||||||||
| 减：利息收入和其他 | $ | (27,884) | Healthpeak的非合并联营企业营业费用分配 | $ | 59,159 | ||||||||||||
| 门诊医疗 | 16,707 | 门诊医疗 | (7,889) | ||||||||||||||
| 实验室 | 14,404 | 实验室 | (52) | ||||||||||||||
| CCRC | — | CCRC | — | ||||||||||||||
| 其他 | 64,797 | 其他 | — | ||||||||||||||
| 企业非区段 | — | 企业非区段 | — | ||||||||||||||
| Healthpeak的非合并合资房地产业收入份额 | $ | 95,908 | 非控股权益的合并联营企业营业费用分配 | $ | (7,941) | ||||||||||||
| 门诊医疗 | (27,952) | 门诊医疗 | (4,299) | ||||||||||||||
| 实验室 | (196) | 实验室 | 862 | ||||||||||||||
| CCRC | — | CCRC | 1,645 | ||||||||||||||
| 其他 | — | 其他 | (251) | ||||||||||||||
| 企业非区段 | — | 企业非区段 | — | ||||||||||||||
| 非控股利益份额占合并合资房地产业收入 | $ | (28,148) | 对营业费用的非现金调整 | $ | (2,043) | ||||||||||||
| 门诊医疗 | (31,872) | 门诊医疗 | 293,647 | ||||||||||||||
| 实验室 | (50,762) | 实验室 | 183,044 | ||||||||||||||
| CCRC | — | CCRC | 322,454 | ||||||||||||||
| 其他 | (145) | 其他 | 47,865 | ||||||||||||||
| 企业非区段 | — | 企业非区段 | — | ||||||||||||||
| 房地产业收入的非现金调整 | $ | (82,779) | 投资组合现金营业费用(2) | $ | 847,010 | ||||||||||||
| 门诊医疗 | 845,329 | 门诊医疗 | 29,131 | ||||||||||||||
| 实验室 | 627,065 | 生命科学 | — | ||||||||||||||
| CCRC | 422,512 | CCRC | — | ||||||||||||||
| 其他 | 64,652 | 其他 | — | ||||||||||||||
| 企业非区段 | — | 企业非部门 | — | ||||||||||||||
投资组合现金房地产营业收入(1) | $ | 1,959,558 | 合并前的传统医疗房地产信托现金营业费用 | $ | 29,131 | ||||||||||||
持续
| 17 | ||||
| 协调 | ||
| 营业收入 | 研究和开发 | |||||||
以千为单位
| 九个月已结束 2024年9月30日 | 九个月已结束 2024年9月30日 | ||||||||||||||||
| 门诊医疗 | $ | 90,529 | 门诊医疗 | $ | (31,378) | ||||||||||||
| 实验室 | — | 实验室 | (31,204) | ||||||||||||||
| CCRC | — | CCRC | (1,702) | ||||||||||||||
| 其他 | — | 其他 | (47,865) | ||||||||||||||
| 企业非细分市场 | — | 企业非细分市场 | — | ||||||||||||||
| 合并前的遗产 Physicians Realty Trust 现金房地产收入 | $ | 90,529 | 合并合并后的非 SS 现金运营费用 | $ | (112,149) | ||||||||||||
| 门诊医疗 | (76,485) | 门诊医疗 | 291,400 | ||||||||||||||
| 实验室 | (113,111) | 实验室 | 151,840 | ||||||||||||||
| CCRC | (909) | CCRC | 320,752 | ||||||||||||||
| 其他 | (64,652) | 其他 | — | ||||||||||||||
| 企业非细分市场 | — | 企业非细分市场 | — | ||||||||||||||
| 合并后的非 SS 现金房地产收入 | $ | (255,157) | 合并合并后的 SS 现金运营费用(3) | $ | 763,992 | ||||||||||||
| 门诊医疗 | 859,373 | ||||||||||||||||
| 实验室 | 513,954 | ||||||||||||||||
| CCRC | 421,603 | ||||||||||||||||
| 其他 | — | ||||||||||||||||
| 企业非细分市场 | — | ||||||||||||||||
合并后的SS现金房地产收入(3) | $ | 1,794,930 | |||||||||||||||
______________________________________
(1)投资组合现金房地产收入消除了直线租金、市场租赁无形资产摊销、租赁终止费以及递延社区费收入的影响。
(2)投资组合现金营业费用消除了直线租金、租约终止费用、已发生但尚未报告的保险索赔的精算准备以及延期社区费用支出的影响。
(3)合并后的同店现金房地产收入和合并后的同店现金营业费用包括符合同店定义的传统Physicians Realty Trust房产的运营结果，就好像它们在所展示的全部期间内被公司拥有一样。
| 18 | ||||
| 协调 | ||
| 分段组合净运营收入和现金（调整后）净运营收入、组合收入和SS | ||
以千为单位
| 总投资组合 | 三个月之内结束 | |||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度报告 2023 | 截至12月31日公允价值 2023 | 3月31号 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| $ | 68,656 | $ | 75,395 | $ | 11,177 | $ | 152,716 | $ | 92,738 | |||||||||||||||||||||||
| 利息收入和其他 | (5,360) | (4,979) | (5,751) | (7,832) | (14,301) | |||||||||||||||||||||||||||
| 利息支出 | 50,510 | 52,784 | 60,907 | 74,910 | 74,105 | |||||||||||||||||||||||||||
| 折旧和摊销 | 184,559 | 188,544 | 219,219 | 283,498 | 280,019 | |||||||||||||||||||||||||||
| ZSCALER, INC. | 23,093 | 21,556 | 23,299 | 26,718 | 23,216 | |||||||||||||||||||||||||||
| 交易和合并相关成本 | 36 | 14,417 | 107,220 | 7,759 | 7,134 | |||||||||||||||||||||||||||
| 净减值损失和贷款损失准备 | (550) | (5,445) | 11,458 | (553) | 441 | |||||||||||||||||||||||||||
| 房地产业销售净收益（损失） | — | — | (3,255) | (122,044) | (62,325) | |||||||||||||||||||||||||||
| 其他（收入）支出，净额 | (1,481) | (2,600) | (78,516) | (4,004) | (982) | |||||||||||||||||||||||||||
| 所得税（收益）费用 | 787 | (11,842) | 13,698 | 2,728 | 1,938 | |||||||||||||||||||||||||||
| 合营创业公司的股权（收入）损失 | (2,101) | (3,558) | (2,376) | (51) | 3,834 | |||||||||||||||||||||||||||
| Healthpeak在非合并创业公司净营业收入中的份额 | 7,045 | 8,295 | 10,627 | 12,800 | 13,324 | |||||||||||||||||||||||||||
| 非控制权益在合并创业公司净营业收入中的份额 | (6,382) | (6,390) | (6,566) | (6,756) | (6,883) | |||||||||||||||||||||||||||
| 非物业级净营业收入 | — | (4,174) | — | — | — | |||||||||||||||||||||||||||
净营业收入调整(1) | (13,416) | (14,361) | (27,609) | (25,232) | (27,899) | |||||||||||||||||||||||||||
| 投资组合调整后的净营业收入 | $ | 305,396 | $ | 307,642 | $ | 333,532 | $ | 394,657 | $ | 384,359 | ||||||||||||||||||||||
| 合并前的传统physicians realty trust调整后的净营业收入 | 78,814 | 42,563 | 61,398 | — | — | |||||||||||||||||||||||||||
| 合并后的非同店调整净营业收入 | (47,449) | (11,083) | (50,255) | (45,324) | (33,672) | |||||||||||||||||||||||||||
合并后的自有物业净营业收入调整后(2) | $ | 336,761 | $ | 339,122 | $ | 344,675 | $ | 349,333 | $ | 350,687 | ||||||||||||||||||||||
门诊医疗 | 三个月之内结束 | |||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度报告 2023 | 截至12月31日公允价值 2023 | 3月31号 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| $ | 48,906 | $ | 48,580 | $ | 49,684 | $ | 108,586 | $ | 94,960 | |||||||||||||||||||||||
| 利息支出 | 1,947 | 1,979 | 3,131 | 4,070 | 4,268 | |||||||||||||||||||||||||||
| 折旧和摊销 | 72,736 | 74,067 | 106,292 | 173,408 | 168,120 | |||||||||||||||||||||||||||
| 交易和合并相关成本 | 23 | 949 | 113 | 41 | 889 | |||||||||||||||||||||||||||
| 房地产业销售的（收益）损失，净额 | — | — | (3,255) | (66,831) | (62,325) | |||||||||||||||||||||||||||
| 其他（收入）支出，净额 | (78) | (2,180) | (71) | (1,383) | 78 | |||||||||||||||||||||||||||
| 与未纳入合并财务报表的合营企业相关的股权（收益）损失 | (211) | (251) | 1,110 | 2,922 | 5,185 | |||||||||||||||||||||||||||
| Healthpeak在未纳入合并财务报表的合营企业净营业收入中的份额 | 445 | 493 | 1,656 | 4,439 | 4,233 | |||||||||||||||||||||||||||
| 非控股权益在合并财务报表中的合营企业净营业收入中的份额 | (6,261) | (6,267) | (6,446) | (6,732) | (6,883) | |||||||||||||||||||||||||||
净营业收入的调整(1) | (3,547) | (2,938) | (6,127) | (10,430) | (11,020) | |||||||||||||||||||||||||||
| 投资组合调整后的净营业收入 | $ | 113,960 | $ | 114,432 | $ | 146,087 | $ | 208,090 | $ | 197,505 | ||||||||||||||||||||||
| 合并前的传统physicians realty trust调整后的净营业收入 | 78,814 | 42,563 | 61,398 | — | — | |||||||||||||||||||||||||||
| 合并后的非同店调整净营业收入 | (6,370) | 29,881 | (19,495) | (18,288) | (4,766) | |||||||||||||||||||||||||||
合并后的SS调整后的净营业收入(2) | $ | 186,404 | $ | 186,876 | $ | 187,990 | $ | 189,802 | $ | 192,739 | ||||||||||||||||||||||
持续
| 19 | ||||
| 协调 | ||
| 分段投资组合净营业收入和现金（调整后）净营业收入，投资组合收入和SS | ||
以千为单位
| 实验室 | 三个月之内结束 | |||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度报告 2023 | 截至12月31日公允价值 2023 | 3月31号 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| $ | 88,337 | $ | 86,913 | $ | 169,798 | $ | 138,830 | $ | 85,240 | |||||||||||||||||||||||
| 折旧和摊销 | 78,646 | 80,886 | 78,908 | 75,947 | 77,625 | |||||||||||||||||||||||||||
| 交易和合并相关成本 | 51 | 124 | 9 | 478 | 4 | |||||||||||||||||||||||||||
| 房地产业销售的净(收益)损失 | — | — | — | (55,213) | — | |||||||||||||||||||||||||||
| 其他（收入）支出，净额 | 1 | (6) | (78,983) | (185) | 402 | |||||||||||||||||||||||||||
| 股权(收入)分担未纳入合并范围的合资公司损失 | (1,244) | (1,384) | (2,811) | (2,247) | (1,754) | |||||||||||||||||||||||||||
| Healthpeak在未纳入合并范围的合资企业的分担净运营收入 | 1,467 | 2,302 | 3,537 | 2,773 | 3,431 | |||||||||||||||||||||||||||
| 非控制利益在合并范围内的合资企业净运营收入中的份额 | (121) | (123) | (120) | (24) | — | |||||||||||||||||||||||||||
对净运营收入的调整(1) | (9,842) | (10,907) | (21,435) | (13,289) | (16,900) | |||||||||||||||||||||||||||
| 投资组合调整后净营业收入 | $ | 157,295 | $ | 157,805 | $ | 148,903 | $ | 147,070 | $ | 148,048 | ||||||||||||||||||||||
| 合并后的非同店调整净营业收入 | (36,305) | (35,286) | (25,701) | (21,356) | (23,651) | |||||||||||||||||||||||||||
合并后净营业收入(2) | $ | 120,990 | $ | 122,519 | $ | 123,202 | $ | 125,714 | $ | 124,397 | ||||||||||||||||||||||
| CCRC | 三个月之内结束 | |||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度报告 2023 | 截至12月31日公允价值 2023 | 3月31号 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| $ | (5,633) | $ | (6,213) | $ | (2,172) | $ | (160) | $ | (2,827) | |||||||||||||||||||||||
| 利息支出 | 1,830 | 1,541 | 996 | 984 | 984 | |||||||||||||||||||||||||||
| 折旧和摊销 | 33,177 | 33,591 | 34,019 | 34,143 | 34,274 | |||||||||||||||||||||||||||
| 交易和合并相关成本 | (85) | 1,469 | 73 | (24) | — | |||||||||||||||||||||||||||
| 其他（收入）支出，净额 | (254) | 33 | 239 | 479 | 694 | |||||||||||||||||||||||||||
调整净利润(1) | — | (940) | — | (1,739) | 95 | |||||||||||||||||||||||||||
| 投资组合调整后的净利润 | $ | 29,035 | $ | 29,481 | $ | 33,155 | $ | 33,683 | $ | 33,220 | ||||||||||||||||||||||
| 合并后的非同店调整净营业收入 | 332 | 246 | 328 | 134 | 331 | |||||||||||||||||||||||||||
合并后的自存库调整后净利润(2) | $ | 29,367 | $ | 29,727 | $ | 33,483 | $ | 33,817 | $ | 33,551 | ||||||||||||||||||||||
| 其他 | 三个月之内结束 | |||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度报告 2023 | 截至12月31日公允价值 2023 | 3月31号 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| $ | 6,503 | $ | 12,338 | $ | (5,724) | $ | 8,195 | $ | 12,282 | |||||||||||||||||||||||
| 利息收入和其他 | (5,360) | (4,979) | (5,059) | (6,878) | (13,126) | |||||||||||||||||||||||||||
| 减值损失和贷款准备金，净 | (550) | (5,445) | 11,458 | (553) | 441 | |||||||||||||||||||||||||||
| 其他（收入）支出，净额 | 53 | 9 | — | (38) | — | |||||||||||||||||||||||||||
| 其他（损失）联营企业的股权收益 | (646) | (1,923) | (675) | (726) | 403 | |||||||||||||||||||||||||||
| Healthpeak在非合并联营企业净营业收入中所占比例 | 5,133 | 5,500 | 5,434 | 5,588 | 5,660 | |||||||||||||||||||||||||||
调整后的净营业收入(1) | (27) | 424 | (47) | 226 | (74) | |||||||||||||||||||||||||||
| 组合调整后的净营业收入 | $ | 5,106 | $ | 5,924 | $ | 5,387 | $ | 5,814 | $ | 5,586 | ||||||||||||||||||||||
| 合并后的非同店调整净营业收入 | (5,106) | (5,924) | (5,387) | (5,814) | (5,586) | |||||||||||||||||||||||||||
合并后的SS调整净运营收入(2) | $ | — | $ | — | $ | — | $ | — | $ | — | ||||||||||||||||||||||
持续
| 20 | ||||
| Reconciliations | ||
| Segment Portfolio NOI and Cash (Adjusted) NOI, Portfolio Income, and SS | ||
In thousands
Corporate Non-Segment | Three Months Ended | |||||||||||||||||||||||||||||||
| September 30, 2023 | December 31, 2023 | March 31, 2024 | June 30, 2024 | September 30, 2024 | ||||||||||||||||||||||||||||
| Net income (loss) | $ | (69,457) | $ | (66,223) | $ | (200,409) | $ | (102,735) | $ | (96,917) | ||||||||||||||||||||||
| Interest income and other | — | — | (692) | (954) | (1,175) | |||||||||||||||||||||||||||
| Interest expense | 46,733 | 49,264 | 56,780 | 69,856 | 68,853 | |||||||||||||||||||||||||||
| General and administrative | 23,093 | 21,556 | 23,299 | 26,718 | 23,216 | |||||||||||||||||||||||||||
| Transaction and merger-related costs | 47 | 11,875 | 107,025 | 7,264 | 6,241 | |||||||||||||||||||||||||||
| Other (income) expense, net | (1,203) | (456) | 299 | (2,877) | (2,156) | |||||||||||||||||||||||||||
| Income tax (benefit) expense | 787 | (11,842) | 13,698 | 2,728 | 1,938 | |||||||||||||||||||||||||||
| Non-property level NOI | — | (4,174) | — | — | — | |||||||||||||||||||||||||||
Merger-Combined SS Adjusted NOI(2) | $ | — | $ | — | $ | — | $ | — | $ | — | ||||||||||||||||||||||
| 21 | ||||
| Reconciliations | ||
| Segment Portfolio NOI and Cash (Adjusted) NOI, Portfolio Income, and SS | ||
In thousands
For the nine months ended September 30, 2024
| Outpatient Medical | Lab | CCRC | Other Non- reportable | Corporate Non-segment | Total | |||||||||||||||||||||||||||||||||
| Net income (loss) | $ | 253,425 | $ | 393,912 | $ | (5,159) | $ | 14,753 | $ | (400,300) | $ | 256,631 | ||||||||||||||||||||||||||
| Interest income and other | — | — | — | (25,063) | (2,821) | (27,884) | ||||||||||||||||||||||||||||||||
| Interest expense | 11,231 | — | 2,963 | — | 195,728 | 209,922 | ||||||||||||||||||||||||||||||||
| Depreciation and amortization | 447,819 | 232,480 | 102,437 | — | — | 782,736 | ||||||||||||||||||||||||||||||||
| General and administrative | — | — | — | — | 73,233 | 73,233 | ||||||||||||||||||||||||||||||||
| Transaction and merger-related costs | 1,043 | 490 | 49 | — | 120,531 | 122,113 | ||||||||||||||||||||||||||||||||
| Impairments and loan loss reserves, net | — | — | — | 11,346 | — | 11,346 | ||||||||||||||||||||||||||||||||
| (Gain) loss on sales of real estate, net | (132,369) | (55,255) | — | — | — | (187,624) | ||||||||||||||||||||||||||||||||
| Other (income) expense, net | (1,376) | (78,766) | 1,413 | (38) | (4,735) | (83,502) | ||||||||||||||||||||||||||||||||
| Income tax (benefit) expense | — | — | — | — | 18,364 | 18,364 | ||||||||||||||||||||||||||||||||
| Equity (income) loss from unconsolidated joint ventures | 9,218 | (6,813) | — | (998) | — | 1,407 | ||||||||||||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture NOI | 10,327 | 9,741 | — | 16,681 | — | 36,749 | ||||||||||||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture NOI | (20,063) | (144) | — | — | — | (20,207) | ||||||||||||||||||||||||||||||||
Adjustments to NOI(1) | (27,573) | (51,624) | (1,645) | 106 | — | (80,736) | ||||||||||||||||||||||||||||||||
| Portfolio Adjusted NOI | $ | 551,682 | $ | 444,021 | $ | 100,058 | $ | 16,787 | $ | — | $ | 1,112,548 | ||||||||||||||||||||||||||
| Pre-Merger legacy Physicians Realty Trust Adjusted NOI | 61,398 | — | — | — | — | 61,398 | ||||||||||||||||||||||||||||||||
| Merger-Combined non-SS Adjusted NOI | (45,107) | (81,907) | 793 | (16,787) | — | (143,008) | ||||||||||||||||||||||||||||||||
Merger-Combined SS Adjusted NOI(2) | $ | 567,973 | $ | 362,114 | $ | 100,851 | $ | — | $ | — | $ | 1,030,938 | ||||||||||||||||||||||||||
| 22 | ||||
| Reconciliations | ||
| Segment Portfolio NOI and Cash (Adjusted) NOI, Portfolio Income, and SS | ||
In thousands
For the nine months ended September 30, 2023
| Outpatient Medical | Lab | CCRC | Other Non- reportable | Corporate Non-segment | Total | |||||||||||||||||||||||||||||||||
| Net income (loss) | $ | 168,037 | $ | 298,145 | $ | (20,374) | $ | 24,445 | $ | (210,891) | $ | 259,362 | ||||||||||||||||||||||||||
| Interest income and other | — | — | — | (16,802) | — | (16,802) | ||||||||||||||||||||||||||||||||
| Interest expense | 5,791 | — | 5,470 | — | 136,286 | 147,547 | ||||||||||||||||||||||||||||||||
| Depreciation and amortization | 215,617 | 247,463 | 98,277 | — | — | 561,357 | ||||||||||||||||||||||||||||||||
| General and administrative | — | — | — | — | 73,576 | 73,576 | ||||||||||||||||||||||||||||||||
| Transaction and merger-related costs | 171 | 209 | 412 | — | 2,306 | 3,098 | ||||||||||||||||||||||||||||||||
| Impairments and loan loss reserves, net | — | — | — | (156) | — | (156) | ||||||||||||||||||||||||||||||||
| (Gain) loss on sales of real estate, net | (21,312) | (60,498) | — | (4,653) | — | (86,463) | ||||||||||||||||||||||||||||||||
| Other (income) expense, net | (517) | (1) | (260) | 72 | (3,502) | (4,208) | ||||||||||||||||||||||||||||||||
| Government grant income | — | — | 184 | — | — | 184 | ||||||||||||||||||||||||||||||||
| Income tax (benefit) expense | — | — | — | — | 2,225 | 2,225 | ||||||||||||||||||||||||||||||||
| Equity (income) loss from unconsolidated joint ventures | (585) | (3,155) | — | (2,906) | — | (6,646) | ||||||||||||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture NOI | 1,350 | 3,532 | — | 16,346 | — | 21,228 | ||||||||||||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture NOI | (18,887) | (341) | — | — | — | (19,228) | ||||||||||||||||||||||||||||||||
Adjustments to NOI(1) | (11,373) | (25,618) | (679) | (59) | — | (37,729) | ||||||||||||||||||||||||||||||||
| Portfolio Adjusted NOI | $ | 338,292 | $ | 459,736 | $ | 83,030 | $ | 16,287 | $ | — | $ | 897,345 | ||||||||||||||||||||||||||
| Pre-Merger legacy Physicians Realty Trust Adjusted NOI | 233,483 | — | — | — | — | 233,483 | ||||||||||||||||||||||||||||||||
| Merger-Combined non-SS Adjusted NOI | (21,755) | (108,446) | 855 | (16,287) | — | (145,633) | ||||||||||||||||||||||||||||||||
Merger-Combined SS Adjusted NOI(2) | $ | 550,020 | $ | 351,290 | $ | 83,885 | $ | — | $ | — | $ | 985,195 | ||||||||||||||||||||||||||
(1)Adjustments to NOI eliminates the effects of straight-line rents, amortization of market lease intangibles, lease termination fees, the impact of deferred community fee income, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fees expense.
(2)Merger-Combined Same-Store Adjusted NOI include the results from operations of the legacy Physicians Realty Trust properties that met the same-store definition as if they were owned by the Company for the entirety of the periods presented.
| 23 | ||||
| Reconciliations | ||
| Property Count Reconciliations | ||
| As of September 30, 2024 | |||||||||||||||||||||||||||||
| Property Count Reconciliation | |||||||||||||||||||||||||||||
| Outpatient Medical | Lab | CCRC | Other | Total | |||||||||||||||||||||||||
| Prior Quarter Total Property Count | 585 | 139 | 15 | 19 | 758 | ||||||||||||||||||||||||
| Assets sold | (59) | — | — | — | (59) | ||||||||||||||||||||||||
| New Developments | 1 | — | — | — | 1 | ||||||||||||||||||||||||
| Current Quarter Total Property Count | 527 | 139 | 15 | 19 | 700 | ||||||||||||||||||||||||
| Recent acquisitions | (3) | — | — | — | (3) | ||||||||||||||||||||||||
| Assets in Development | (7) | (4) | — | — | (11) | ||||||||||||||||||||||||
| Recently completed Developments | (1) | (1) | — | — | (2) | ||||||||||||||||||||||||
| Assets in Redevelopment | — | (17) | — | — | (17) | ||||||||||||||||||||||||
| Recently completed Redevelopments | (3) | (4) | — | — | (7) | ||||||||||||||||||||||||
| Segment exclusions | — | — | — | (19) | (19) | ||||||||||||||||||||||||
| Significant tenant relocation | — | (2) | — | — | (2) | ||||||||||||||||||||||||
| Three-Month SS Property Count | 513 | 111 | 15 | — | 639 | ||||||||||||||||||||||||
| Recent acquisitions | (2) | — | — | — | (2) | ||||||||||||||||||||||||
| Recently completed Redevelopments | (1) | (1) | — | — | (2) | ||||||||||||||||||||||||
| Nine-Month SS Property Count | 510 | 110 | 15 | — | 635 | ||||||||||||||||||||||||
| Sequential SS | |||||||||||||||||||||||||||||
| Outpatient Medical | Lab | CCRC | Other | Total | |||||||||||||||||||||||||
| Prior Quarter Three-Month SS Property Count | 569 | 112 | 15 | — | 696 | ||||||||||||||||||||||||
| Acquisitions | 2 | — | — | — | 2 | ||||||||||||||||||||||||
| Assets in Redevelopment | — | (1) | — | — | (1) | ||||||||||||||||||||||||
| Prior Development/Redevelopment | 1 | 1 | — | — | 2 | ||||||||||||||||||||||||
| Significant tenant relocation | — | (1) | — | — | (1) | ||||||||||||||||||||||||
| Assets sold | (59) | — | — | — | (59) | ||||||||||||||||||||||||
| Current Quarter Three-Month SS Property Count | 513 | 111 | 15 | — | 639 | ||||||||||||||||||||||||
| 24 | ||||
| Reconciliations | ||
| Common Stock and Equivalents | ||
| Weighted Average Shares | Weighted Average Shares | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended September 30, 2024 | Nine Months Ended September 30, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares Outstanding September 30, 2024 | Diluted EPS | Diluted Nareit FFO | Diluted FFO as Adjusted | Diluted AFFO | Diluted EPS | Diluted Nareit FFO | Diluted FFO as Adjusted | Diluted AFFO | |||||||||||||||||||||||||||||||||||||||||||||
| Common stock | 699,405 | 699,349 | 699,349 | 699,349 | 699,349 | 667,536 | 667,536 | 667,536 | 667,536 | ||||||||||||||||||||||||||||||||||||||||||||
Common stock equivalent securities(1): | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Restricted stock units | 963 | 137 | 137 | 137 | 137 | 150 | 150 | 150 | 150 | ||||||||||||||||||||||||||||||||||||||||||||
| OP units | 3,177 | 660 | 1,606 | 1,606 | 1,606 | 410 | 1,190 | 1,190 | 1,190 | ||||||||||||||||||||||||||||||||||||||||||||
| Convertible partnership units | 13,558 | — | 13,623 | 13,623 | 13,623 | — | 12,252 | 12,252 | 12,252 | ||||||||||||||||||||||||||||||||||||||||||||
| Total common stock and equivalents | 717,103 | 700,146 | 714,715 | 714,715 | 714,715 | 668,096 | 681,128 | 681,128 | 681,128 | ||||||||||||||||||||||||||||||||||||||||||||
______________________________________
(1)The weighted average shares for the three months ended September 30, 2024 represent the current dilutive impact, using the treasury stock method, of approximately 1.0 million restricted stock units, 3.2 million OP Units, and 13.6 million DownREIT units.
| 25 | ||||
| Reconciliations | ||
| Net Income to Adjusted EBITDAre | ||
In thousands
| Three Months Ended September 30, 2024 | |||||
| Net income (loss) | $ | 92,738 | |||
| Interest expense | 74,105 | ||||
| Income tax expense (benefit) | 1,938 | ||||
| Depreciation and amortization | 280,019 | ||||
| Other depreciation and amortization | 807 | ||||
| Loss (gain) on sales of real estate | (62,325) | ||||
| Loss (gain) upon change of control | 430 | ||||
| Share of unconsolidated JV: | |||||
| Interest expense | 5,859 | ||||
| Income tax expense (benefit) | 24 | ||||
| Depreciation and amortization | 12,127 | ||||
| EBITDAre | $ | 405,722 | |||
| Transaction and merger-related items | 2,743 | ||||
| Other impairments (recoveries) and other losses (gains) | 441 | ||||
| Casualty-related charges (recoveries) | 2,074 | ||||
| Stock-based compensation amortization expense | 3,755 | ||||
Impact of transactions closed during the period(1) | (598) | ||||
| Adjusted EBITDAre | $ | 414,137 | |||
Impact of transactions closed during the period(1) | 598 | ||||
Fixed Charge Coverage Adjusted EBITDAre(2) | $ | 414,735 | |||
| Adjusted Fixed Charge Coverage | ||
In thousands
| Three Months Ended September 30, 2024 | |||||
| Interest expense, including unconsolidated JV interest expense at share | $ | 79,964 | |||
| Capitalized interest, including unconsolidated JV capitalized interest at share | 16,681 | ||||
| Fixed Charges | $ | 96,645 | |||
| Adjusted Fixed Charge Coverage | 4.3x | ||||
______________________________________
(1)Adjustment reflects the impact of transactions that closed during the period as if the transactions were completed at the beginning of the period.
(2)Fixed Charge Coverage Adjusted EBITDAre is utilized in the calculation of Adjusted Fixed Charge Coverage and excludes the impact of transactions that closed during the period for consistency with the calculation of Fixed Charges.
| 26 | ||||
| Reconciliations | ||
| Enterprise Debt and Net Debt | ||
In thousands
| 2024年9月30日 | |||||
| 期限贷款 | $ | 1,645,748 | |||
| 高级无担保票据 | 6,557,170 | ||||
| 抵押债务 | 380,459 | ||||
| 合并债务 | $ | 8,583,377 | |||
| 非合并企业债务股份 | 186,356 | ||||
| 企业债务 | $ | 8,769,733 | |||
| 现金及现金等价物 | (180,430) | ||||
| 未纳入合并的合营企业现金及现金等价物份额 | (30,851) | ||||
| 受限现金 | (61,615) | ||||
| 未纳入合并的合营企业受限现金份额 | (5,357) | ||||
| 净债务 | $ | 8,491,480 | |||
| 财务杠杆 | ||
以千为单位
| 2024年9月30日 | |||||
| 企业债务 | $ | 8,769,733 | |||
| 企业总资产 | 24,934,139 | ||||
| 财务杠杆 | 35.2% | ||||
| 担保债务比率 | ||
以千为单位
| 2024年9月30日 | |||||
| 抵押债务 | $ | 380,459 | |||
| 未纳入合并范围的JV按揭债务份额 | 186,356 | ||||
| 企业担保债务 | $ | 566,815 | |||
| 企业总资产 | $ | 24,934,139 | |||
| 担保债务比率 | 2.3% | ||||
| 净负债与调整后的EBITDAre比率 | ||
以千为单位
| 2024年9月30日 | |||||
| 净债务 | $ | 8,491,480 | |||
年化调整后的EBITDAre(1) | 1,656,548 | ||||
| 净债务与调整后的EBITDAre比率 | 5.1倍 | ||||
______________________________________
(1)代表当前季度的调整后的息税折旧及摊销前利润乘以四倍。
| 27 | ||||
| 协调 | ||
| Healthpeak的非合并合资企业净营业收入份额 | ||
以千为单位
| 总投资组合 | 三个月已结束 | ||||||||||||||||||||||||||||
| 9月30日 2023 | 十二月 31, 2023 | 三月三十一日 2024 | 6月30日 2024 | 九月三十日 2024 | |||||||||||||||||||||||||
| 来自未合并合资企业的股权收益（亏损） | $ | 2,101 | $ | 3,558 | $ | 2,376 | $ | 51 | $ | (3,834) | |||||||||||||||||||
| 折旧和摊销 | 6,190 | 6,724 | 8,772 | 11,621 | 12,127 | ||||||||||||||||||||||||
| 一般和行政 | 267 | 199 | 337 | 79 | 353 | ||||||||||||||||||||||||
| 其他（收入）支出，净额 | (1,558) | (2,389) | (1,005) | 883 | 4,670 | ||||||||||||||||||||||||
| 所得税（福利）支出 | 45 | 203 | 147 | 166 | 8 | ||||||||||||||||||||||||
| Healthpeak 在未合并合资企业 NOI 中的份额 | $ | 7,045 | $ | 8,295 | $ | 10,627 | $ | 12,800 | $ | 13,324 | |||||||||||||||||||
| 门诊医疗 | 三个月已结束 | ||||||||||||||||||||||||||||
| 9月30日 2023 | 十二月 31, 2023 | 三月三十一日 2024 | 6月30日 2024 | 九月三十日 2024 | |||||||||||||||||||||||||
| 来自未合并合资企业的股权收益（亏损） | $ | 211 | $ | 251 | $ | (1,110) | $ | (2,922) | $ | (5,185) | |||||||||||||||||||
| 折旧和摊销 | 218 | 241 | 1,615 | 4,270 | 4,253 | ||||||||||||||||||||||||
| 一般和行政 | 15 | (3) | 44 | 133 | 91 | ||||||||||||||||||||||||
| 其他（收入）支出，净额 | — | — | 1,099 | 2,965 | 5,082 | ||||||||||||||||||||||||
| 所得税（福利）支出 | 1 | 4 | 8 | (7) | (8) | ||||||||||||||||||||||||
| Healthpeak 在未合并合资企业 NOI 中的份额 | $ | 445 | $ | 493 | $ | 1,656 | $ | 4,439 | $ | 4,233 | |||||||||||||||||||
| 实验室 | 三个月已结束 | ||||||||||||||||||||||||||||
| 9月30日 2023 | 十二月 31, 2023 | 三月三十一日 2024 | 6月30日 2024 | 九月三十日 2024 | |||||||||||||||||||||||||
| 来自未合并合资企业的股权收益（亏损） | $ | 1,244 | $ | 1,384 | $ | 2,811 | $ | 2,247 | $ | 1,754 | |||||||||||||||||||
| 折旧和摊销 | 1,568 | 1,992 | 2,573 | 2,693 | 3,194 | ||||||||||||||||||||||||
| 一般和行政 | 220 | 134 | 217 | (53) | 242 | ||||||||||||||||||||||||
| 其他（收入）支出，净额 | (1,565) | (1,208) | (2,064) | (2,114) | (1,759) | ||||||||||||||||||||||||
| Healthpeak 在未合并合资企业 NOI 中的份额 | $ | 1,467 | $ | 2,302 | $ | 3,537 | $ | 2,773 | $ | 3,431 | |||||||||||||||||||
| 其他 | 三个月已结束 | ||||||||||||||||||||||||||||
| 9月30日 2023 | 十二月 31, 2023 | 三月三十一日 2024 | 6月30日 2024 | 九月三十日 2024 | |||||||||||||||||||||||||
| 来自未合并合资企业的股权收益（亏损） | $ | 646 | $ | 1,923 | $ | 675 | $ | 726 | $ | (403) | |||||||||||||||||||
| 折旧和摊销 | 4,404 | 4,491 | 4,584 | 4,658 | 4,680 | ||||||||||||||||||||||||
| 一般和行政 | 32 | 68 | 76 | (1) | 20 | ||||||||||||||||||||||||
| 其他（收入）支出，净额 | 7 | (1,181) | (40) | 32 | 1,347 | ||||||||||||||||||||||||
| 所得税（福利）支出 | 44 | 199 | 139 | 173 | 16 | ||||||||||||||||||||||||
| Healthpeak 在未合并合资企业 NOI 中的份额 | $ | 5,133 | $ | 5,500 | $ | 5,434 | $ | 5,588 | $ | 5,660 | |||||||||||||||||||
| 28 | ||||
| 协调 | ||
| Healthpeak的非合并合资企业净营业收入份额 | ||
以千为单位
截至2024年9月30日止九个月
| 门诊 医疗 | 实验室 | 其他 | 总费用 | |||||||||||||||||||||||
| 来自未纳入合并报表的合营公司的股权收入（亏损） | $ | (9,217) | $ | 6,812 | $ | 998 | $ | (1,407) | ||||||||||||||||||
| 折旧和摊销 | 10,138 | 8,460 | 13,922 | 32,520 | ||||||||||||||||||||||
| ZSCALER, INC. | 267 | 406 | 95 | 768 | ||||||||||||||||||||||
| 其他（收入）支出，净额 | 9,146 | (5,937) | 1,338 | 4,547 | ||||||||||||||||||||||
| 所得税（收益）费用 | (7) | — | 328 | 321 | ||||||||||||||||||||||
| Healthpeak在未纳入合并范围的合资企业的分担净运营收入 | $ | 10,327 | $ | 9,741 | $ | 16,681 | $ | 36,749 | ||||||||||||||||||
2023年9月30日结束的九个月内的合同余额
| 门诊 医疗 | 实验室 | 其他 | 总费用 | |||||||||||||||||||||||
| 与未纳入合并范围的合资企业的股权收益（损失） | $ | 585 | $ | 3,155 | $ | 2,906 | $ | 6,646 | ||||||||||||||||||
| 折旧和摊销 | 712 | 4,504 | 12,860 | 18,076 | ||||||||||||||||||||||
| ZSCALER, INC. | 41 | 774 | 143 | 958 | ||||||||||||||||||||||
| 其他（收入）支出，净额 | — | (4,901) | (47) | (4,948) | ||||||||||||||||||||||
| 所得税（收益）费用 | 12 | — | 484 | 496 | ||||||||||||||||||||||
| Healthpeak在未纳入合并范围的合资企业的分担净运营收入 | $ | 1,350 | $ | 3,532 | $ | 16,346 | $ | 21,228 | ||||||||||||||||||
| 29 | ||||
| 协调 | ||
| 非控股权益在合并的合资创业公司中的净营业收入份额 | ||
以千为单位
| 总投资组合 | 三个月已结束 | ||||||||||||||||||||||||||||
| 9月30日 2023 | 十二月 31, 2023 | 三月三十一日 2024 | 6月30日 2024 | 九月三十日 2024 | |||||||||||||||||||||||||
| 归因于非控股权益的持续经营收入（亏损） | $ | 4,442 | $ | 4,451 | $ | 4,501 | $ | 6,669 | $ | 6,866 | |||||||||||||||||||
| 折旧和摊销 | 4,474 | 4,502 | 4,452 | 4,614 | 4,415 | ||||||||||||||||||||||||
| 其他（收入）支出，净额 | 6 | 23 | 124 | 84 | 207 | ||||||||||||||||||||||||
| 归属于非控股权益的股息 | (2,540) | (2,586) | (2,511) | (4,611) | (4,605) | ||||||||||||||||||||||||
| 非控股权益在合并合资企业NOI中的份额 | $ | 6,382 | $ | 6,390 | $ | 6,566 | $ | 6,756 | $ | 6,883 | |||||||||||||||||||
| 门诊医疗 | 三个月已结束 | ||||||||||||||||||||||||||||
| 9月30日 2023 | 十二月 31, 2023 | 三月三十一日 2024 | 6月30日 2024 | 九月三十日 2024 | |||||||||||||||||||||||||
| 归因于非控股权益的持续经营收入（亏损） | $ | 3,181 | $ | 3,162 | $ | 3,266 | $ | 5,398 | $ | 5,661 | |||||||||||||||||||
| 折旧和摊销 | 4,422 | 4,452 | 4,402 | 4,603 | 4,415 | ||||||||||||||||||||||||
| 其他（收入）支出，净额 | 97 | 117 | 215 | 107 | 177 | ||||||||||||||||||||||||
| 归属于非控股权益的股息 | (1,439) | (1,464) | (1,437) | (3,376) | (3,370) | ||||||||||||||||||||||||
| 非控股权益在合并合资企业NOI中的份额 | $ | 6,261 | $ | 6,267 | $ | 6,446 | $ | 6,732 | $ | 6,883 | |||||||||||||||||||
| 实验室 | 三个月已结束 | ||||||||||||||||||||||||||||
| 9月30日 2023 | 十二月 31, 2023 | 三月三十一日 2024 | 6月30日 2024 | 九月三十日 2024 | |||||||||||||||||||||||||
| 归因于非控股权益的持续经营收入（亏损） | $ | 1,061 | $ | 1,093 | $ | 1,044 | $ | 949 | $ | 883 | |||||||||||||||||||
| 折旧和摊销 | 52 | 50 | 50 | 11 | — | ||||||||||||||||||||||||
| 其他（收入）支出，净额 | (91) | (94) | (91) | (23) | 30 | ||||||||||||||||||||||||
| 归属于非控股权益的股息 | (901) | (926) | (883) | (913) | (913) | ||||||||||||||||||||||||
| 非控股权益在合并合资企业NOI中的份额 | $ | 121 | $ | 123 | $ | 120 | $ | 24 | $ | — | |||||||||||||||||||
| 企业非区段 | 三个月之内结束 | ||||||||||||||||||||||||||||
| 截至2023年9月30日年
度报告 2023 | 截至12月31日公允价值 2023 | 3月31日 2024 | 6月30日, 2024 | 2020年9月30日 2024 | |||||||||||||||||||||||||
| 持续经营业务可归属于非控制权益的损益 | $ | 200 | $ | 196 | $ | 191 | $ | 322 | $ | 322 | |||||||||||||||||||
| 归属于非控股权益的分红派息 | (200) | (196) | (191) | (322) | (322) | ||||||||||||||||||||||||
| 非控制利益在合并范围内的合资企业净运营收入中的份额 | $ | — | $ | — | $ | — | $ | — | $ | — | |||||||||||||||||||
| 30 | ||||
| 协调 | ||
| 非控股权益在合并的合资创业公司中的净营业收入份额 | ||
以千为单位
截至2024年9月30日止九个月
| 门诊 医疗 | 实验室 | 企业 非分段 | 总计 | |||||||||||||||||||||||
| 归因于非控股权益的持续经营收入（亏损） | $ | 14,325 | $ | 2,876 | $ | 835 | $ | 18,036 | ||||||||||||||||||
| 折旧和摊销 | 13,420 | 61 | — | 13,481 | ||||||||||||||||||||||
| 其他（收入）支出，净额 | 501 | (84) | — | 417 | ||||||||||||||||||||||
| 归属于非控股权益的股息 | (8,183) | (2,709) | (835) | (11,727) | ||||||||||||||||||||||
| 非控股权益在合并合资企业NOI中的份额 | $ | 20,063 | $ | 144 | $ | — | $ | 20,207 | ||||||||||||||||||
2023年9月30日结束的九个月内的合同余额
| 门诊 医疗 | 实验室 | 公司 非分段 | 总费用 | |||||||||||||||||||||||
| 持续经营业务可归属于非控制权益的损益 | $ | 20,285 | $ | 3,622 | $ | 390 | $ | 24,297 | ||||||||||||||||||
| 房地产业销售净收益（损失） | (11,133) | (413) | — | (11,546) | ||||||||||||||||||||||
| 折旧和摊销 | 13,617 | 141 | — | 13,758 | ||||||||||||||||||||||
| 其他（收入）支出，净额 | 438 | (277) | — | 161 | ||||||||||||||||||||||
| 归属于非控股权益的分红派息 | (4,320) | (2,732) | (390) | (7,442) | ||||||||||||||||||||||
| 非控制权益在合并创业公司净营业收入中的份额 | $ | 18,887 | $ | 341 | $ | — | $ | 19,228 | ||||||||||||||||||
| 31 | ||||
| 协调 | ||
REVOR CCRC(1) | ||
以千为单位，除每月数据外
| 三个月之内结束 | |||||||||||||||||||||||||||||
| REVPOR CCRC | 截至2023年9月30日年
度报告 2023 | 截至12月31日公允价值 2023 | 3月31日 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||
投资组合现金房地产营业收入(2) | $ | 133,808 | $ | 136,340 | $ | 138,777 | $ | 140,890 | $ | 142,845 | |||||||||||||||||||
CCRC的其他调整(3) | (206) | — | — | — | — | ||||||||||||||||||||||||
| CCRC营收 | $ | 133,603 | $ | 136,340 | $ | 138,777 | $ | 140,890 | $ | 142,845 | |||||||||||||||||||
| 每月平均入住单位 | 5,956 | 6,031 | 6,043 | 6,049 | 6,013 | ||||||||||||||||||||||||
每月CCRC每单位收入(4) | $ | 7,477 | $ | 7,536 | $ | 7,655 | $ | 7,764 | $ | 7,919 | |||||||||||||||||||
| 三个月之内结束 | |||||||||||||||||||||||||||||
| 不包括NREF摊销的REVPOR CCRC | 截至2023年9月30日年
度报告 2023 | 截至12月31日公允价值 2023 | 3月31日 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||
| REVPOR CCRC营收 | $ | 133,603 | $ | 136,340 | $ | 138,777 | $ | 140,890 | $ | 142,845 | |||||||||||||||||||
| 非现金化摊销 | (20,762) | (22,105) | (21,577) | (21,401) | (22,622) | ||||||||||||||||||||||||
| REVPOR长期照护产生的收入，不包括非现金化摊销 | $ | 112,841 | $ | 114,235 | $ | 117,200 | $ | 119,489 | $ | 120,223 | |||||||||||||||||||
| 每月平均入住单位数 | 5,956 | 6,031 | 6,043 | 6,049 | 6,013 | ||||||||||||||||||||||||
REVPOR长期照护产生的收入，每月不包括非现金化摊销(4) | $ | 6,315 | $ | 6,314 | $ | 6,465 | $ | 6,585 | $ | 6,665 | |||||||||||||||||||
_____________________________________
(1)可能不准确，因为四舍五入。
(2)查看本文档的第13页和第14页，了解投资组合现金房地产收入的调解情况.
(3)包括2023年9月30日结束的三个月内尚未稳定的改建中或最近完成的设施的营业收入。
(4)代表每间客房每半天收入（REVPOR）除以三的比例。
| 32 | ||||
| 协调 | ||
REVPOR(1) | ||
以千为单位，除每月数据外
| 三个月之内结束 | |||||||||||||||||||||||||||||
| 其他REVPOR | 截至2023年9月30日年
度报告 2023 | 截至12月31日公允价值 2023 | 3月31日 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||
投资组合现金房地产营业收入(2) | $ | 20,567 | $ | 21,167 | $ | 21,477 | $ | 21,360 | $ | 21,815 | |||||||||||||||||||
对REVPOR的其他调整(3) | (2,456) | — | — | — | — | ||||||||||||||||||||||||
| REVPOR收入 | $ | 18,111 | $ | 21,167 | $ | 21,477 | $ | 21,360 | $ | 21,815 | |||||||||||||||||||
| 每月平均入住单位数 | 1,320 | 1,410 | 1,401 | 1,415 | 1,450 | ||||||||||||||||||||||||
每月REVPOR(4) | $ | 4,573 | $ | 5,005 | $ | 5,109 | $ | 5,032 | $ | 5,016 | |||||||||||||||||||
______________________________________
(1)可能不准确，因为四舍五入。
(2)请查看本文档第13页和第14页，了解投资组合现金房地产收入的调解。
(3)包括2023年9月30日结束的三个月中尚未稳定的资产再开发或最近完成的再开发的收入。
(4)表示季度REVPOR除以三的倍数。
| 33 | ||||
前瞻性声明
非依据通用证券诉讼改革法案，非依据历史事实的所有声明均属于“前瞻性声明”。这些前瞻性声明可能包含我们目前预期、估计和对我们的管理人员所做假设的行业和市场以及我方所在地区的信仰，涉及可能严重影响我们的财务或经营结果的不确定性。诸如“预期”、“预测”、“意图”、“计划”、“相信”、“寻求”、“估计”、“预测”、“计划”、“预测”、“将会”、“可能”的词语，以及这些词语和类似表达的变体，旨在识别此类前瞻性声明。此类前瞻性声明包括关于我们的业务展望、2024年的指引、未来收购、处置、发展、融资活动、租赁活动、财务和经营结果、计划、目标、预期和意图的声明
| 34 | ||||